

NEWPORT CORP  
Form 10-Q  
November 10, 2005  
Table of Contents

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

---

**FORM 10-Q**

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended October 1, 2005

OR

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number: 000-01649

---

**NEWPORT CORPORATION**

*(Exact name of registrant as specified in its charter)*

Edgar Filing: NEWPORT CORP - Form 10-Q

**Nevada**  
*(State or other jurisdiction of  
incorporation or organization)*

**94-0849175**  
*(IRS Employer Identification No.)*

**1791 Deere Avenue, Irvine, California 92606**

*(Address of principal executive offices) (Zip Code)*

**Registrant's telephone number, including area code: (949) 863-3144**

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  No

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).

Yes  No

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes  No

As of October 28, 2005, 39,940,060 shares of the registrant's sole class of common stock were outstanding.

---

---

**Table of Contents**

**NEWPORT CORPORATION**

**FORM 10-Q**

**INDEX**

	<b>Page</b>
	<b>Number</b>
<hr/>	
<b>PART I. FINANCIAL INFORMATION</b>	
Item 1. Financial Statements:	
<u>Consolidated Statements of Operations for the Three and Nine Months Ended October 1, 2005 and October 2, 2004</u>	3
<u>Consolidated Balance Sheets as of October 1, 2005 and January 1, 2005</u>	4
<u>Consolidated Statements of Cash Flows for the Nine Months Ended October 1, 2005 and October 2, 2004</u>	5
<u>Notes to Consolidated Financial Statements</u>	6
<u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	18
<u>Item 3. Quantitative and Qualitative Disclosures About Market Risk</u>	41
<u>Item 4. Controls and Procedures</u>	42
<b>PART II. OTHER INFORMATION</b>	
<u>Item 5. Unregistered Sales of Equity Securities and Use of Proceeds</u>	43
<u>Item 6. Exhibits</u>	43
<u><b>SIGNATURES</b></u>	44

**Table of Contents****PART I FINANCIAL INFORMATION****ITEM 1. FINANCIAL STATEMENTS****NEWPORT CORPORATION****Consolidated Statements of Operations****(In thousands, except per share data)****(Unaudited)**

	<u>Three Months Ended</u>		<u>Nine Months Ended</u>	
	<u>October 1,</u>	<u>October 2,</u>	<u>October 1,</u>	<u>October 2,</u>
	<u>2005</u>	<u>2004</u>	<u>2005</u>	<u>2004</u>
Net sales	\$ 103,005	\$ 90,354	\$ 299,871	\$ 168,724
Cost of sales	59,309	62,422	174,690	113,265
Gross profit	43,696	27,932	125,181	55,459
Selling, general and administrative expense	25,964	26,873	76,202	45,922
Research and development expense	9,066	7,364	26,718	13,434
Operating income (loss)	8,666	(6,305)	22,261	(3,897)
Interest and other expense, net	(690)	(3,740)	(1,887)	(1,184)
Income (loss) from continuing operations before income taxes	7,976	(10,045)	20,374	(5,081)
Income tax provision	1,108	932	2,995	772
Income (loss) from continuing operations before extraordinary gain	6,868	(10,977)	17,379	(5,853)
Loss from discontinued operations, net of income tax benefit of \$1,360, \$0, \$2,120 and \$0, respectively	(9,123)	(7,554)	(15,177)	(8,830)
Extraordinary gain on settlement of litigation			2,891	
Net income (loss)	\$ (2,255)	\$ (18,531)	\$ 5,093	\$ (14,683)
Basic income (loss) per share:				
Income (loss) from continuing operations before extraordinary gain	\$ 0.17	\$ (0.26)	\$ 0.42	\$ (0.15)
Loss from discontinued operations, net of income taxes	(0.23)	(0.18)	(0.37)	(0.22)
Extraordinary gain on settlement of litigation			0.07	
Net income (loss)	\$ (0.06)	\$ (0.44)	\$ 0.12	\$ (0.37)
Diluted income (loss) per share:				

Edgar Filing: NEWPORT CORP - Form 10-Q

Income (loss) from continuing operations before extraordinary gain	\$ 0.17	\$ (0.26)	\$ 0.40	\$ (0.15)
Loss from discontinued operations, net of income taxes	(0.22)	(0.18)	(0.35)	(0.22)
Extraordinary gain on settlement of litigation			0.07	
	<u>          </u>	<u>          </u>	<u>          </u>	<u>          </u>
Net income (loss)	\$ (0.05)	\$ (0.44)	\$ 0.12	\$ (0.37)
	<u>          </u>	<u>          </u>	<u>          </u>	<u>          </u>
Shares used in the computation of income (loss) per share:				
Basic	39,688	42,190	41,769	40,204
Diluted	41,094	42,190	43,245	40,204

See accompanying notes.

**Table of Contents****NEWPORT CORPORATION****Consolidated Balance Sheets****(In thousands, except share data)****(Unaudited)**

	<b>October 1,</b>	<b>January 1,</b>
	<b>2005</b>	<b>2005</b>
	<b>_____</b>	<b>_____</b>
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents	\$ 32,428	\$ 41,443
Marketable securities	30,879	66,739
Accounts receivable, net of allowance for doubtful accounts of \$1,135 and \$2,057, respectively	72,283	63,334
Notes receivable, net	4,420	6,891
Inventories	75,804	75,257
Prepaid expenses and other current assets	9,079	8,710
Assets of discontinued operations	7,453	18,400
	<b>_____</b>	<b>_____</b>
Total current assets	232,346	280,774
Property and equipment, net	49,505	55,577
Goodwill	176,433	176,235
Intangible assets, net	51,391	54,420
Investments and other assets	9,624	11,462
	<b>_____</b>	<b>_____</b>
	<b>\$ 519,299</b>	<b>\$ 578,468</b>
	<b>_____</b>	<b>_____</b>
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
Current liabilities:		
Short-term obligations	\$ 12,018	\$ 17,186
Accounts payable	22,808	23,018
Accrued payroll and related expenses	19,786	20,619
Accrued expenses and other current liabilities	25,379	31,442
Accrued restructuring costs	1,485	2,672
Obligations under capital leases	76	161
Liabilities of discontinued operations	1,914	3,474
	<b>_____</b>	<b>_____</b>
Total current liabilities	83,466	98,572
Long-term debt	49,914	46,716
Obligations under capital leases, less current portion	1,338	1,576
Accrued pension liabilities	10,743	11,410
Accrued restructuring costs and other liabilities	3,153	4,685
Commitments and contingencies		
Stockholders' equity:		
Common stock, par value \$0.1167 per share, 200,000,000 shares authorized; 39,919,512 and 43,022,866 shares issued and outstanding, respectively	4,659	5,021
Capital in excess of par value	448,776	493,986
Deferred stock compensation	(461)	(1,379)

Edgar Filing: NEWPORT CORP - Form 10-Q

Accumulated other comprehensive income	3,207	8,470
Accumulated deficit	(85,496)	(90,589)
	<u>          </u>	<u>          </u>
Total stockholders' equity	370,685	415,509
	<u>          </u>	<u>          </u>
	\$ 519,299	\$ 578,468
	<u>          </u>	<u>          </u>

See accompanying notes.

**Table of Contents****NEWPORT CORPORATION****Consolidated Statements of Cash Flows****(In thousands)****(Unaudited)**

	<b>Nine Months Ended</b>	
	<b>October 1, 2005</b>	<b>October 2, 2004</b>
<b>CASH FLOWS FROM OPERATING ACTIVITIES:</b>		
Net income (loss)	\$ 5,093	\$ (14,683)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:		
Depreciation and amortization	15,071	13,202
Provision for loss on disposal of assets of discontinued operations	9,182	
Provision for losses on inventories	821	4,731
Investment write-down	454	1,419
Provision for restructuring	135	684
Gain on disposal of property and equipment	(411)	(173)
Provision for doubtful accounts	(540)	175
Extraordinary gain on settlement of litigation	(2,891)	
Increase (decrease) in cash due to changes in:		
Accounts and notes receivable	(9,825)	(10,334)
Inventories	(2,061)	9,141
Prepaid expenses and other current assets	(715)	293
Other assets and liabilities	(361)	143
Accounts payable	(609)	1,629
Accrued payroll and related expenses	(982)	4,534
Accrued expenses and other current liabilities	(6,162)	1,746
Accrued restructuring costs	(2,687)	(1,402)
<b>Net cash provided by operating activities</b>	<b>3,512</b>	<b>11,105</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>		
Purchase of property and equipment	(6,951)	(2,714)
Proceeds from the sale of property and equipment	704	11
Purchase of marketable securities	(238,735)	(286,927)
Proceeds from the sale of marketable securities	273,543	493,841
Business acquisitions, net of cash acquired		(203,668)
Proceeds from sale of business and equity investments	1,849	
Purchase of equity investments		(410)
<b>Net cash provided by investing activities</b>	<b>30,410</b>	<b>133</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES:</b>		
Repayment of long-term debt and obligations under capital leases	(185)	(287)
Short-term borrowings (repayments), net	769	1,843
Purchases of the Company's common stock	(46,209)	
Proceeds from the issuance of common stock under employee plans	4,288	3,468



Edgar Filing: NEWPORT CORP - Form 10-Q

Net cash provided by (used in) financing activities	(41,337)	5,024
Impact of foreign exchange rate changes on cash balances	(1,600)	53
Net increase (decrease) in cash and cash equivalents	(9,015)	16,315
Cash and cash equivalents at beginning of period	41,443	11,795
Cash and cash equivalents at end of period	\$ 32,428	\$ 28,110
Supplemental disclosures of cash flow information:		
Cash paid during the period for:		
Interest	\$ 2,238	\$ 335
Income taxes paid (refunds received), net	\$ 3,572	\$ (269)
Supplemental disclosures of non-cash investing and financing activities:		
Issuance of common stock in connection with business acquisition	\$	\$ 48,079
Issuance of debt in connection with business acquisition	\$	\$ 46,382

See accompanying notes.

**Table of Contents**

**NEWPORT CORPORATION**

**Notes to Consolidated Financial Statements**

**October 1, 2005**

**NOTE 1 BASIS OF PRESENTATION**

The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. These financial statements are unaudited and have been prepared in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, all adjustments (consisting of normal and recurring accruals and acquisition-related items) considered necessary for a fair presentation have been included. All significant intercompany transactions and balances have been eliminated in consolidation.

The accompanying consolidated financial statements do not include certain footnotes and financial presentations normally required under generally accepted accounting principles (GAAP) and, therefore, should be read in conjunction with the consolidated financial statements and related notes contained in the Company's Annual Report on Form 10-K for the year ended January 1, 2005. The results for the interim periods are not necessarily indicative of results for the full year ending December 31, 2005. The January 1, 2005 balances reported herein are derived from the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended January 1, 2005.

Certain prior period amounts have been reclassified to conform to the current period presentation.

**NOTE 2 ACQUISITION**

In July 2004, the Company acquired all of the issued and outstanding capital stock of Spectra-Physics, Inc. and certain related entities (collectively, Spectra-Physics). Spectra-Physics manufactures high-power solid-state, gas and dye lasers, high-power laser diodes, and ultrafast laser systems, as well as other photonic components and devices used in a wide range of applications, including scientific research, industrial and microelectronics manufacturing and analytical instrumentation for life and health sciences. The combination created a leading photonics company with an integrated technology mix.

The transaction was accounted for using the purchase method. The Company's results of operations for 2004 included the results of operations of Spectra-Physics from the date of acquisition on July 16, 2004.

The purchase price for Spectra-Physics, which resulted in the recognition of goodwill of \$175.5 million, was determined by arms-length negotiation between management and Thermo Electron Corporation, Spectra-Physics' former parent company, taking into account a number of factors, including the value of the assets, the historical and projected financial performance of Spectra-Physics and the valuations of certain recently acquired companies with comparable businesses and financial performance.

The aggregate purchase price was approximately \$275.4 million, which consisted of approximately \$174.9 million in cash, \$48.1 million in common stock of the Company, \$46.4 million in debt and \$6.0 million in other costs, which primarily consisted of professional fees related to

## Edgar Filing: NEWPORT CORP - Form 10-Q

the acquisition. The cash portion of the purchase price paid at the closing of the transaction in July 2004 was \$200 million; however, the purchase price was subject to a net asset adjustment, which resulted in a payment of approximately \$25.1 million by Thermo Electron Corporation to the Company in the fourth quarter of 2004.

Page 6

**Table of Contents****NEWPORT CORPORATION****Notes to Consolidated Financial Statements****October 1, 2005**

Below is a summary of the final purchase price, assets acquired and liabilities assumed:

**(In thousands, except share amounts)**

<b>Consideration paid:</b>	
Cash paid	\$ 174,870
3,220,300 shares of common stock, valued based upon the average price two days before and after the measurement date	48,079
Debt (\$50 million, 5% interest payable quarterly, principal due in full July 16, 2009, discounted to market value)	46,382
Other costs, primarily professional fees	6,078
	<u>\$ 275,409</u>
<b>Assets acquired and liabilities assumed:</b>	
Current assets	\$ 93,355
Goodwill	175,450
Purchased intangible assets (including in-process R&D of \$0.3 million)	58,400
Other assets	37,142
Current liabilities	(77,516)
Long-term liabilities	(11,422)
	<u>\$ 275,409</u>

The number of shares of the Company's common stock issued was determined by dividing \$50.0 million by the average closing price of the Company's common stock for the 20 trading days ending two days before the acquisition date of July 16, 2004, which was \$15.53 per share. The fair value of the Company's common stock issued was determined using an average price of \$14.93, which was the average closing price of the Company's common stock two days before and after the measurement date of July 14, 2004.

The debt, which has a principal amount of \$50.0 million and bears interest at 5% per annum, was valued at approximately \$46.4 million on the date of acquisition, based upon the present value of cash flows, using a discount rate of 6.75% in order to reflect a market rate of interest for similar debt with similar characteristics.

In connection with the acquisition of Spectra-Physics, the Company's Board of Directors approved a preliminary restructuring plan to consolidate certain locations. In connection with the finalization of the restructuring plan, which was completed in the third quarter of 2005, the Company adjusted the purchase price allocation recorded in 2004 against goodwill by approximately \$0.2 million, which included a net reduction of certain accrued liabilities recorded on the acquisition date that were no longer required, a reduction of the estimated fair value recorded for fixed assets at certain closed facilities and an increase of certain incurred direct costs of the acquisition.

Identifiable intangible assets consisted of the following:

<u>(In thousands)</u>	<u>Estimated</u>	<u>Weighted Average</u> <u>Amortization</u>	<u>Estimated</u> <u>Annual</u>
	<u>Fair Value</u>	<u>Period</u>	<u>Amortization</u>
Developed technology	\$ 24,500	10-16 years	\$ 1,801
Customer relationships	19,500	10 years	1,950
Backlog	2,200	6 months	2,200
	<u>46,200</u>		
Amortizable purchased intangible assets			
Trademark/tradename	11,900	Indefinite	
	<u>\$ 58,100</u>		

Approximately \$0.3 million of the purchase price represented purchased in-process technology that had not yet reached technological feasibility and has no alternative future use and has been expensed.

**Table of Contents****NEWPORT CORPORATION****Notes to Consolidated Financial Statements****October 1, 2005***Supplemental Pro Forma Information*

The financial information below summarizes the combined results of operations of the Company and Spectra-Physics, on a pro forma basis, as though the companies had been combined as of the beginning of 2004. This pro forma financial information is presented for information purposes only and is not necessarily indicative of the results of operations that would have been achieved had the acquisition taken place at the beginning of the periods presented. The pro forma condensed combined statement of operations for the three and nine months ended October 2, 2004 includes the historical results of the Company, plus the historical results of Spectra-Physics for the three and nine months ended October 2, 2004:

<u>(In thousands)</u>	<b>Three Months</b>	<b>Nine Months</b>
	<b>Ended October 2, 2004</b>	<b>Ended October 2, 2004</b>
Pro forma net sales	\$ 96,995	\$ 291,010
Pro forma income (loss) from continuing operations before extraordinary gain	(3,181)	4,172
Pro forma net loss	(10,735)	(4,658)
Pro forma basic net loss per share	(0.25)	(0.11)
Pro forma diluted net loss per share	(0.25)	(0.10)

**NOTE 3 DISCONTINUED OPERATIONS**

Following the acquisition of Spectra-Physics, the Company conducted a strategic review of all of its businesses and concluded that the Company's robotic systems operations in Richmond, California were no longer core to the Company's strategy. Consequently, in the first quarter of 2005, the Company's Board of Directors approved a plan to sell these operations, which serve the front-end semiconductor equipment industry with product lines including wafer-handling robots, load ports and equipment front-end modules. At that time, the Company classified its robotic systems operations as discontinued operations. In October 2005, the Company announced that it had entered into a definitive agreement to sell its robotic systems operations, and the Company expects to complete the sale in the fourth quarter of 2005. The robotic systems operations were included in the Company's former Advanced Packaging and Automation Systems (APAS) Division.

In the third quarter of 2005, the Company determined that it would have ongoing cash flows with an identifiable component of this operation. Accordingly, the results of operations for this component for all periods presented have been reclassified into continuing operations. The remaining robotic systems operations have been accounted for as discontinued operations for all periods presented. The amounts of this component that were included in continuing operations are as follows:

<b>Three Months Ended</b>	<b>Nine Months Ended</b>
---------------------------	--------------------------

Edgar Filing: NEWPORT CORP - Form 10-Q

<u>(In thousands)</u>	October 1,	October 2,	October 1,	October 2,
	2005	2004	2005	2004
Net sales	\$ 1,230	\$ 1,212	\$ 3,585	\$ 3,530
Income (loss) before income taxes	350	(56)	949	(393)

The net sales and loss before income taxes from the discontinued operations consisted of the following:

<u>(In thousands)</u>	<u>Three Months Ended</u>		<u>Nine Months Ended</u>	
	October 1,	October 2,	October 1,	October 2,
	2005	2004	2005	2004
Net sales	\$ 1,804	\$ 3,281	\$ 7,321	\$ 14,810
Loss before income taxes	(10,483)	(7,554)	(17,297)	(8,830)

**Table of Contents**

**NEWPORT CORPORATION**

**Notes to Consolidated Financial Statements**

**October 1, 2005**

In the third quarter of 2005, the Company recorded a \$9.2 million adjustment to reduce the carrying amount of the assets disposed to reflect the expected consideration for the sale, less estimated selling costs.

**NOTE 4 DERIVATIVE INSTRUMENTS**

The Company recognizes all derivative financial instruments in the consolidated financial statements at fair value regardless of the purpose or intent for holding the instrument. The accounting for changes in the fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and further, on the type of hedging relationship. The Company does not engage in currency speculation; however, the Company uses forward exchange contracts to mitigate the risks associated with certain foreign currency transactions entered into in the ordinary course of business, primarily foreign currency denominated receivables and payables. Such contracts do not qualify for hedge accounting and, accordingly, changes in fair values are reported in the statements of operations. The forward exchange contracts generally require the Company to exchange U.S. dollars for foreign currencies at maturity, at rates agreed to at the inception of the contracts. If the counterparties to the exchange contracts (AA or A+ rated banks) do not fulfill their obligations to deliver the contracted currencies, the Company could be at risk for any currency-related fluctuations. Transaction gains and losses are included in the statements of operations in *interest and other income (expense), net*.

There were no foreign exchange contracts outstanding as of October 1, 2005 or January 1, 2005.

**NOTE 5 ACCOUNTS AND NOTES RECEIVABLE**

The Company records reserves for specific receivables deemed to be at risk for collection, as well as a reserve based on the Company's historical collections experience. The Company estimates the collectibility of customer receivables on an ongoing basis by reviewing past due invoices and assessing the current creditworthiness of each customer. A considerable amount of judgment is required in assessing the ultimate realization of these receivables. In the first quarter of 2005, the Company revised its method of estimating its reserve based upon the Company's historical collections experience. As a result of this revision, the allowance for doubtful accounts was reduced by approximately \$0.7 million in the first quarter of 2005, which reduced *selling, general and administrative expense* for the nine months ended October 1, 2005 in the accompanying statement of operations.

Certain of the Company's Japanese customers provide the Company with promissory notes on the due date of the receivable. The payment date of the promissory notes is generally 90 days from the original receivable due date. Subsequently, certain of these promissory notes are sold with recourse under line of credit agreements to one of four banks within Japan with which the Company does business. Such transactions are conducted in the ordinary course of business. For balance sheet presentation purposes, amounts due to the Company under such promissory notes are reclassified from accounts receivable to current notes receivable. At October 1, 2005 and January 1, 2005, total promissory notes receivable amounted to \$4.4 million and \$6.9 million, respectively. The principal amount of promissory notes sold with recourse is included in both *notes receivable, net* and *short-term obligations* until the underlying note obligations are ultimately satisfied by payment by the customers to the banks. At October 1, 2005 and January 1, 2005, the principal amounts of such promissory notes included in *notes receivable, net* and *short-term obligations* in the accompanying consolidated balance sheet were \$2.1 million and \$4.3 million, respectively.



**NOTE 6 REVENUE RECOGNITION**

The Company recognizes revenue after title to and risk of loss of products have passed to the customer (which typically occurs upon shipment from the Company's facilities), or delivery of the service has been completed, provided that persuasive evidence of an arrangement exists, the fee is fixed or determinable and collectibility is probable. The Company recognizes revenue and related costs for arrangements with multiple deliverables, such as equipment and installation, as each element is delivered or completed based upon its relative fair value, determined based upon the price that would be charged on a standalone basis. However, if a portion of the total contract price is not payable until installation is complete, the Company does not recognize such portion as revenue until completion of installation; however, the Company does record the full cost of the product at the time of shipment. Revenues for training are deferred until the service is completed. Revenues for extended service contracts are recognized over the related contract periods.

Table of Contents

## NEWPORT CORPORATION

## Notes to Consolidated Financial Statements

October 1, 2005

Customers generally have 30 days from the original invoice date (generally 60 days for international customers) to return a standard catalog product purchase for exchange or credit. Catalog products must be returned in the original condition and meet certain other criteria. Product returns of catalog items have historically been insignificant and are charged against revenue in the period returned. Custom, option-configured and certain other products as defined in the terms and conditions of sale cannot be returned. For certain non-catalog products, the Company establishes a sales return reserve based on the historical product returns.

**NOTE 7 STOCK-BASED COMPENSATION**

The Company applies the intrinsic value based method of accounting prescribed by Accounting Principles Board (APB) Opinion No. 25, *Accounting for Stock Issued to Employees* and related Interpretations in accounting for its stock-based compensation and complies with the disclosure provisions of Statement of Financial Accounting Standards (SFAS) No. 148, *Accounting for Stock-Based Compensation Transition and Disclosure* and SFAS No. 123, *Accounting for Stock-Based Compensation*. Accordingly, no compensation expense is recognized for employee stock options with exercise prices greater than or equal to the Company's stock price at the date of grant. Costs related to restricted stock grants, representing the difference between the grant date fair value of the award and the purchase price, if any, of the related shares, are fixed at the date of grant and amortized over the vesting period. Pro forma amounts adjusted for the effect of recording compensation cost related to the Company's stock option and employee stock purchase plans determined based upon the fair value of awards under these plans as of the grant date, consistent with the methodology prescribed under SFAS No. 148 and SFAS No. 123, are presented below:

	Three Months Ended		Nine Months Ended	
	October 1,	October 2,	October 1,	October 2,
	2005	2004	2005	2004
<b>(In thousands, except per share data)</b>				
Net income (loss) reported	\$ (2,255)	\$ (18,531)	\$ 5,093	\$ (14,683)
Employee compensation expense under fair value method	(2,051)	(4,242)	(5,568)	(11,380)
Net loss pro forma	\$ (4,306)	\$ (22,773)	\$ (475)	\$ (26,063)
Basic net income (loss) per share reported	\$ (0.06)	\$ (0.44)	\$ 0.12	\$ (0.37)
Basic net loss per share pro forma	(0.11)	(0.54)	(0.01)	(0.65)
Diluted net income (loss) per share reported	\$ (0.05)	\$ (0.44)	\$ 0.12	\$ (0.37)
Diluted net loss per share pro forma	(0.10)	(0.54)	(0.01)	(0.65)
Shares used in computation of income (loss) per share:				
Basic reported and pro forma	39,688	42,190	41,769	40,204
Diluted reported and pro forma	41,094	42,190	43,245	40,204

The fair value of each option granted in 2005 was estimated as of the date of the grant using the Black-Scholes option pricing model with the following weighted-average assumptions: no annualized dividend yield; expected annual volatility of 60.1%; risk-free interest rate of 3.9%; expected life of 5 years; and expected turnover rate of 12.9%.

**NOTE 8 INCOME TAXES**

The Company provides for income taxes in interim periods based on the estimated effective income tax rate for the complete fiscal year. The income tax provision (benefit) is computed on the pretax income (loss) of the consolidated entities located within each taxing jurisdiction based on current tax law. Deferred taxes result from the future tax consequences associated with temporary differences between the amount of assets and liabilities for tax and financial accounting purposes. A valuation allowance for deferred tax assets is recorded to the extent the Company cannot determine, in accordance with the provisions of SFAS No. 109, *Accounting for Income Taxes*, that the ultimate realization of the net deferred tax assets is more likely than not.

**Table of Contents****NEWPORT CORPORATION****Notes to Consolidated Financial Statements****October 1, 2005**

The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers taxable income in carryback years, the scheduled reversal of deferred tax liabilities, tax planning strategies and projected future taxable income in making this assessment. As of October 1, 2005, due to uncertainties surrounding the realization of the Company's cumulative federal and state net operating losses, the Company has recorded a valuation allowance against a portion of its gross deferred tax assets. For the foreseeable future, the Federal tax provision related to future earnings will be substantially offset by a reduction in the valuation reserve, and any future pretax losses will not be offset by a tax benefit due to the uncertainty of the recoverability of the deferred tax assets. Accordingly, current and future tax expense will consist primarily of certain required state income taxes and taxes in certain foreign jurisdictions.

**NOTE 9 INVENTORIES**

Inventories are stated at the lower of cost (determined on either a first in, first-out [FIFO] or average cost basis) or fair market value and include materials, labor and manufacturing overhead. The Company writes down excess and obsolete inventory to net realizable value. In assessing the ultimate realization of inventories, the Company makes judgments as to future demand requirements and compares those requirements with the current or committed inventory levels. Amounts required to reduce the carrying value of inventory to net realizable value are recorded as a charge to cost of sales.

Inventories consisted of the following:

<u>(In thousands)</u>	<b>October 1,</b>	<b>January 1,</b>
	<b>2005</b>	<b>2005</b>
Raw materials and purchased parts	\$ 34,271	\$ 37,628
Work in process	19,655	19,481
Finished goods	21,878	18,148
	<u>\$ 75,804</u>	<u>\$ 75,257</u>

**NOTE 10 ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES**

Accrued expenses and other current liabilities consisted of the following:

<u>(In thousands)</u>	<b>October 1,</b>	<b>January 1,</b>
-----------------------	-------------------	-------------------

	<u>2005</u>	<u>2005</u>
Deferred revenue	\$ 8,237	\$ 9,820
Accrued warranty obligations	4,553	4,890
Other	12,589	16,732
	<u>\$ 25,379</u>	<u>\$ 31,442</u>

**NOTE 11 ACCRUED WARRANTY OBLIGATIONS**

Unless otherwise stated in the Company's product literature or in its agreements with customers, products sold by the Company's Photonics and Precision Technologies Division generally carry a one-year warranty from the original invoice date on all product material and workmanship. Products of such division sold to original equipment manufacturer (OEM) customers generally carry longer warranties, typically 15 to 24 months. Products sold by the Company's Lasers Division generally carry warranties that vary by product and product component, but generally range from 90 days to two years. In certain cases, warranties for Lasers Division products are limited by either a set calendar period or a maximum amount of usage of the product, whichever occurs first. Defective products will be either repaired or replaced, generally at the Company's option, upon meeting certain criteria. The Company accrues a provision (based on historical experience) for the estimated costs that may be incurred for warranties relating to a product as a component of cost of sales at the time revenue for that product is recognized.

Table of Contents

## NEWPORT CORPORATION

## Notes to Consolidated Financial Statements

October 1, 2005

The activity in accrued warranty obligations is as follows:

<u>(In thousands)</u>	<u>Nine Months Ended</u>	
	<u>October 1,</u> <u>2005</u>	<u>October 2,</u> <u>2004</u>
Balance at beginning of year	\$ 4,890	\$ 523
Additions charged to cost of sales	3,958	1,663
Additions from business acquisition		4,504
Warranty claims	(4,295)	(1,526)
Balance at end of period	<u>\$ 4,553</u>	<u>\$ 5,164</u>

Such amounts are included in *accrued expenses and other current liabilities* in the accompanying consolidated balance sheets.

**NOTE 12 ACCRUED RESTRUCTURING COSTS***2004 Restructuring Plan*

In connection with the acquisition of Spectra-Physics, the Company's Board of Directors approved a preliminary restructuring plan to consolidate certain locations, which included \$2.2 million for employee relocation and employee severance and related termination costs and \$3.2 million in costs related to facility consolidations. In the third quarter of 2005, the Company finalized this plan, which included \$3.3 million for employee relocation and employee severance and related termination costs and \$2.2 million related to facility consolidation costs, resulting in a net increase of approximately \$0.1 million from the preliminary plan. This increase resulted in an adjustment to goodwill of approximately \$0.1 million.

The following table summarizes the activity in the accrued restructuring costs related to the purchase of Spectra-Physics, which primarily involve the payment of cash:

<u>(In thousands)</u>	<u>Employee</u>	<u>Facility</u> <u>Consolidation</u>	<u>Total</u>
-----------------------	-----------------	---	--------------

	<b>Relocation and Severance</b>	_____	_____
Accrued restructuring at January 1, 2005	\$ 1,687	\$ 3,186	\$ 4,873
Cash payments	(2,124)	(252)	(2,376)
Adjustments to restructuring plan	1,095	(971)	124
	_____	_____	_____
Accrued restructuring at October 1, 2005	\$ 658	\$ 1,963	\$ 2,621
	_____	_____	_____

The facility consolidation costs will be paid over the term of the lease for the closed facility, which expires in 2011. At October 1, 2005 and January 1, 2005, \$1.0 million and \$2.1 million, respectively, of these accrued restructuring costs were expected to be paid within one year and were included in current liabilities in *accrued restructuring costs*, and \$1.6 million and \$2.8 million, respectively, of accrued restructuring costs were included in long-term liabilities in *accrued restructuring costs and other liabilities*, in the accompanying consolidated balance sheets.

#### *2002 Restructuring Plan*

During 2002, in response to the continued severe downturn in the fiber optic communications market and the uncertainty with respect to the pace of recovery in the semiconductor equipment market, the Company's Board of Directors approved a restructuring and cost reduction plan designed to bring the Company's operating costs in line with its business outlook at that time. In the third quarter of 2005, the Company increased its estimate of the required liability for facility consolidations by \$0.1 million to reflect revised estimates of reduced future sublease income.

**Table of Contents****NEWPORT CORPORATION****Notes to Consolidated Financial Statements****October 1, 2005**

The following table summarizes the activity in accrued restructuring costs related to the 2002 restructuring plan:

<u>(In thousands)</u>	<u>Facility Consolidation</u>
Accrued restructuring at January 1, 2005	\$ 833
Cash payments	(311)
Adjustments to restructuring plan	135
Accrued restructuring at October 1, 2005	<u>\$ 657</u>

As of October 1, 2005, \$0.7 million of facility-related costs remained accrued for under the Company's 2002 restructuring plan. The facility consolidation reserves will be paid over the associated lease terms, which expire at various dates between 2006 and 2008. At October 1, 2005 and January 1, 2005, \$0.5 million and \$0.6 million, respectively, of accrued restructuring costs were expected to be paid within one year and were included in current liabilities in *accrued restructuring costs*, and \$0.2 million of accrued restructuring costs were included in long-term liabilities in *accrued restructuring costs and other liabilities* for both periods, in the accompanying consolidated balance sheets.

**NOTE 13 SHORT-TERM OBLIGATIONS**

At October 1, 2005, the Company had a total of seven lines of credit, including one domestic revolving line of credit, two revolving lines of credit with Japanese banks, and four other lines of credit with Japanese banks which are used to sell trade notes receivable with recourse to the banks.

The Company's domestic revolving line of credit has a total credit limit of \$5.0 million and expires December 1, 2005. Certain of the marketable securities that are being managed by the lending institution collateralize the line of credit. The line bears interest at the prevailing prime rate, or the prevailing London Interbank Offered Rate (3.87% at October 1, 2005) plus 1.5%, at the Company's option, and an unused line fee of 0.25% per year. At October 1, 2005, there were no balances outstanding under the line of credit, with \$1.8 million available under the line, after considering outstanding letters of credit totaling \$3.2 million.

The two revolving lines of credit with Japanese banks total 1.7 billion yen (\$15.0 million at October 1, 2005) and expire as follows: \$7.1 million on November 30, 2005, \$5.3 million on March 18, 2006 and \$2.6 million on June 30, 2008. The lines are not secured and bear interest at the prevailing bank rate. At October 1, 2005, the Company had \$12.4 million outstanding and no amounts available for borrowing under these lines of credit. Approximately \$9.8 million of the amount outstanding under these revolving lines of credit at October 1, 2005 was included in *short-term obligations* in the accompanying balance sheet, and approximately \$2.6 million was included in *long-term debt* as the due date of this portion of the borrowings outstanding is on June 30, 2008.



The four other lines of credit with Japanese banks, which are used to sell notes receivable with recourse, total 800 million yen (\$7.1 million at October 1, 2005), have no expiration date and bear interest at the bank's prevailing rate. At October 1, 2005, the Company had \$2.1 million outstanding and \$5.0 million available for the sale of notes receivable under these lines of credit. The weighted average interest rate on all borrowings on all six Japanese lines of credit as of October 1, 2005 was 1.5%.

**NOTE 14 STOCKHOLDER EQUITY TRANSACTIONS**

In April 2003, the Board of Directors of the Company approved a share repurchase program, authorizing the purchase of up to 3.9 million shares, or 10% of the Company's then-outstanding stock. The purchases may be made from time to time in the open market or in privately negotiated transactions, and the timing and amount of the purchases will be based on factors including the Company's share price, cash balances, expected cash requirements and general business and market conditions. In May 2005, the Company purchased 174,833 shares of its common stock in the open market at an average price of \$13.72 per share for a total of \$2.4 million. In June 2005, the Company purchased 3,220,300 shares of its common stock from Thermo Electron Corporation (Thermo) that were previously issued as part of the consideration for the acquisition of Spectra-Physics from Thermo in July 2004. The Company purchased the shares at a price of \$13.56 per share for a total of \$43.7 million. As of October 1, 2005, 219,038 shares remained available for purchase under the share repurchase program.

**Table of Contents****NEWPORT CORPORATION****Notes to Consolidated Financial Statements****October 1, 2005**

In August 2005, the Company received and cancelled 9,293 shares of common stock in payment of taxes owed on ordinary income recognized by certain employees upon the vesting of shares of restricted stock issued to them under the Company's 2001 Stock Incentive Plan. At the time they were received, these shares had a value of \$13.71 per share for a total of \$0.1 million.

**NOTE 15 INTEREST AND OTHER EXPENSE, NET**

Interest and other expense, net, consisted of the following:

<u>(In thousands)</u>	<u>Three Months Ended</u>		<u>Nine Months Ended</u>	
	<u>October 1,</u>	<u>October 2,</u>	<u>October 1,</u>	<u>October 2,</u>
	<u>2005</u>	<u>2004</u>	<u>2005</u>	<u>2004</u>
Interest and dividend income	\$ 374	\$ 375	\$ 1,678	\$ 2,974
Interest expense	(924)	(804)	(2,780)	(884)
Bank and portfolio asset management fees	(135)	(109)	(381)	(379)
Foreign exchange gains (losses), net	(35)	(74)	28	(20)
Losses on sales of marketable securities, net	(5)	(1,749)	(63)	(1,489)
Investment write-downs		(1,419)	(454)	(1,419)
Other income, net	35	40	85	33
	<u>\$ (690)</u>	<u>\$ (3,740)</u>	<u>\$ (1,887)</u>	<u>\$ (1,184)</u>

**NOTE 16 ACCUMULATED OTHER COMPREHENSIVE INCOME AND COMPREHENSIVE INCOME (LOSS)**

Accumulated other comprehensive income consisted of the following:

<u>(In thousands)</u>	<u>October 1,</u>	<u>January 1,</u>
	<u>2005</u>	<u>2005</u>
Cumulative foreign currency translation gains	\$ 3,536	\$ 8,672
Unrealized losses on marketable securities	(329)	(202)
	<u>\$ 3,207</u>	<u>\$ 8,470</u>

The components of comprehensive income (loss), net of related tax, were as follows:

<u>(In thousands)</u>	<u>Three Months Ended</u>		<u>Nine Months Ended</u>	
	<u>October 1,</u>	<u>October 2,</u>	<u>October 1,</u>	<u>October 2,</u>
	<u>2005</u>	<u>2004</u>	<u>2005</u>	<u>2004</u>
Net income (loss)	\$ (2,255)	\$ (18,531)	\$ 5,093	\$ (14,683)
Foreign currency translation gain (loss)	1,245	1,192	(5,136)	899
Unrealized holding period gains (losses) arising during period	(79)	142	(190)	(1,579)
Less: reclassification adjustments for (gain) loss included in net income (loss)	5	1,749	63	1,489
	<u>\$ (1,084)</u>	<u>\$ (15,448)</u>	<u>\$ (170)</u>	<u>\$ (13,874)</u>

**NOTE 17 EXTRAORDINARY GAIN ON SETTLEMENT OF LITIGATION**

In March 2005, the Company settled a dispute arising out of its acquisition of Micro Robotics Systems, Inc. (MRSI). As a result of this settlement, the Company recorded an extraordinary gain of \$2.9 million in the first quarter of 2005. Pursuant to the terms of the settlement agreement, 114,691 shares of the Company's common stock, which were being held in escrow, were returned to the Company and cancelled. Such shares had been issued to the former MRSI stockholders at the time of the acquisition of MRSI, or had been issued upon the exercise of options to

**Table of Contents****NEWPORT CORPORATION****Notes to Consolidated Financial Statements****October 1, 2005**

purchase the Company's common stock which had been granted at the time of the acquisition in connection with the assumption and conversion of options to purchase MRSI common stock. In addition, outstanding options to purchase 21,606 shares of the Company's common stock were cancelled and the exercise prices of all remaining outstanding and unexercised options which had been granted in connection with the MRSI acquisition were increased to reflect an adjustment to the total consideration paid for the acquisition.

**NOTE 18 NET INCOME (LOSS) PER SHARE**

The following table sets forth the numerator and denominator used in the computation of net income (loss) per share:

<b>(In thousands)</b>	<b>Three Months Ended</b>		<b>Nine Months Ended</b>	
	<b>October 1,</b>	<b>October 2,</b>	<b>October 1,</b>	<b>October 2,</b>
	<b>2005</b>	<b>2004</b>	<b>2005</b>	<b>2004</b>
<b>Numerator for basic and diluted net income (loss) per share:</b>				
Income (loss) from continuing operations before extraordinary item	\$ 6,868	\$ (10,977)	\$ 17,379	\$ (5,853)
Loss from discontinued operations, net of income taxes	(9,123)	(7,554)	(15,177)	(8,830)
Extraordinary gain on settlement of litigation			2,891	
<b>Net income (loss)</b>	<b>\$ (2,255)</b>	<b>\$ (18,531)</b>	<b>\$ 5,093</b>	<b>\$ (14,683)</b>
<b>Denominator for basic and diluted net income (loss) per share:</b>				
Weighted average shares outstanding	39,842	42,352	41,944	40,305
Weighted unvested restricted stock outstanding	(154)	(162)	(175)	(101)
<b>Denominator for basic net income (loss) per share:</b>	<b>39,688</b>	<b>42,190</b>	<b>41,769</b>	<b>40,204</b>
<b>Effect of dilutive securities:</b>				
Employee stock options	1,252		1,301	
Restricted stock	154		175	
<b>Denominator for diluted net income (loss) per share:</b>	<b>41,094</b>	<b>42,190</b>	<b>43,245</b>	<b>40,204</b>

Common stock equivalents 1,456 and 1,847 have been excluded from the denominator for purposes of calculating diluted loss per share for the three and nine months ended October 2, 2004, respectively, as their inclusion would be anti-dilutive due to the losses from continuing operations incurred.

**NOTE 19 DEFINED BENEFIT PENSION PLANS**

Several of the Company's non-U.S. subsidiaries have defined benefit pension plans covering substantially all full-time employees at those subsidiaries. Some of the plans are unfunded, as permitted under the plans and applicable laws. For financial reporting purposes, the calculation of net periodic pension costs is based upon a number of actuarial assumptions, including a discount rate for plan obligations, an assumed rate of return on pension plan assets and an assumed rate of compensation increase for employees covered by the plan. All of these assumptions are based upon management's judgment, considering all known trends and uncertainties. Actual results that differ from these assumptions would impact future expense recognition and the cash funding requirements of our pension plans.

Spectra-Physics was acquired by the Company on July 16, 2004. Accordingly, the pension plan information relating to Spectra-Physics for the three and nine months is presented from the acquisition date only. Pension plan information related to the Company's other subsidiaries for the nine months ended October 2, 2004 is not included as such amounts were not material.

**Table of Contents****NEWPORT CORPORATION****Notes to Consolidated Financial Statements****October 1, 2005**

Net periodic benefit costs for the plans in aggregate included the following components:

<b>(In thousands)</b>	<b>Three Months Ended</b>		<b>Nine Months Ended</b>	
	<b>October 1,</b>	<b>October 2,</b>	<b>October 1,</b>	<b>October 2,</b>
	<b>2005</b>	<b>2004</b>	<b>2005</b>	<b>2004</b>
Service cost	\$ 143	\$ 99	\$ 444	\$ 99
Interest cost on benefit obligation	146	147	452	147
Expected return on plan assets	(34)	(58)	(105)	(58)
	<b>\$ 255</b>	<b>\$ 188</b>	<b>\$ 791</b>	<b>\$ 188</b>

**NOTE 20 SEGMENT REPORTING**

In 2005, in connection with the decision to divest its robotic systems operations, the Company realigned its business segments to eliminate the previously reported Advanced Packaging and Automation Systems Division. Portions of this division were reclassified into the Photonics and Precision Technologies Division and discontinued operations.

The results from all prior periods reflect this change in business segment reporting.

<b>(In thousands)</b>	<b>Lasers</b>	<b>Photonics and Precision Technologies</b>	<b>Total</b>
<b>Three months ended October 1, 2005:</b>			
Sales to external customers	\$ 42,746	\$ 60,259	\$ 103,005
Segment income	3,070	11,847	14,917
<b>Three months ended October 2, 2004:</b>			
Sales to external customers	\$ 39,194	\$ 51,160	\$ 90,354
Segment income	3,051	8,304	11,355
<b>Nine months ended October 1, 2005:</b>			
Sales to external customers	\$ 131,327	\$ 168,544	\$ 299,871
Segment income	10,765	28,835	39,600
<b>Nine months ended October 2, 2004:</b>			

Edgar Filing: NEWPORT CORP - Form 10-Q

Sales to external customers	\$ 39,194	\$ 129,530	\$ 168,724
Segment income	3,051	15,749	18,800

Page 16

Table of Contents

## NEWPORT CORPORATION

## Notes to Consolidated Financial Statements

October 1, 2005

The following reconciles segment income to consolidated income from continuing operations before income taxes:

(In thousands)	Three Months Ended		Nine Months Ended	
	October 1,	October 2,	October 1,	October 2,
	2005	2004	2005	2004
Segment income	\$ 14,917	\$ 11,355	\$ 39,600	\$ 18,800
Integration-related charges to cost of sales		(8,565)		(8,565)
Unallocated operating expenses	(6,251)	(7,957)	(17,339)	(12,904)
Restructuring, impairment, integration and other charges		(1,138)		(1,228)
Interest and other expense, net	(690)	(3,740)	(1,887)	(1,184)
Income (loss) from continuing operations before income taxes	\$ 7,976	\$ (10,045)	\$ 20,374	\$ (5,081)



---

**Table of Contents**

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE THREE AND NINE MONTHS ENDED OCTOBER 1, 2005 AND OCTOBER 2, 2004**

**Introductory Note**

This Quarterly Report on Form 10-Q contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and we intend that such forward-looking statements be subject to the safe harbors created thereby. Words such as may, will, expect, believe, anticipate, intend, could, estimate, or continue or the negative or other thereof or comparable terminology are intended to identify forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our businesses, or other characterizations of future events or circumstances, including statements regarding our expected net sales, gross margins, selling, general and administrative expense, research and development expense, interest and other expense, net, income taxes, cash balances, working capital position, and future cash flows are forward-looking statements.

The forward-looking statements included herein are based on current expectations and involve a number of risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond our control. As such, our actual results may differ significantly from those expressed in any forward-looking statements. Factors that may cause or contribute to such differences include, but are not limited to, those discussed in more detail under the subheading **RISKS RELATING TO OUR BUSINESS** on pages 32 through 41 of this Quarterly Report on Form 10-Q, and in Item 1 (Business) and Item 7 (Management's Discussion and Analysis of Financial Condition and Results of Operations) in our Annual Report on Form 10-K for the year ended January 1, 2005. Readers should carefully review these risks, as well as the additional risks described in other documents we file from time to time with the Securities and Exchange Commission. In light of the significant risks and uncertainties inherent in the forward-looking information included herein, the inclusion of such information should not be regarded as a representation by us or any other person that such results will be achieved, and readers are cautioned not to place undue reliance on such forward-looking information. We undertake no obligation to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

The following is our discussion and analysis of certain significant factors that have affected our earnings and financial position during the periods included in the accompanying financial statements. This discussion compares the three and nine month periods ended October 1, 2005 and October 2, 2004. This discussion should be read in conjunction with the consolidated financial statements and associated notes included elsewhere in this Quarterly Report on Form 10-Q and in conjunction with our Annual Report on Form 10-K for the year ended January 1, 2005.

**Acquisition**

In July 2004, we acquired all of the issued and outstanding capital stock of Spectra-Physics, Inc. and certain related entities (collectively, Spectra-Physics). Spectra-Physics manufactures high-power solid-state, gas and dye lasers, high-power laser diodes and ultrafast laser systems, as well as other photonic components and devices used in a wide range of applications, including scientific research, industrial and microelectronic manufacturing and analytical instrumentation for life and health sciences. The combination created a leading photonics company with an integrated technology mix. The transaction was accounted for using the purchase method. Our results of operations for 2004 included the results of operations of Spectra-Physics from the date of acquisition on July 16, 2004.

**Discontinued Operations**

## Edgar Filing: NEWPORT CORP - Form 10-Q

Following the acquisition of Spectra-Physics, we conducted a strategic review of all of our businesses and concluded that the Company's robotic systems operations in Richmond, California were no longer core to our strategy. Consequently, in the first quarter of 2005, our Board of Directors approved a plan to sell these operations, which serve the front-end semiconductor equipment industry with product lines including wafer-handling robots, load ports and equipment front-end modules. At that time, we classified our robotic systems operations as discontinued operations. In October 2005, we announced that we had entered into a definitive agreement to sell our robotic

Page 18

**Table of Contents**

systems operations, and we expect to complete the sale in the fourth quarter of 2005. The robotic systems operations were included in our former Advanced Packaging and Automation Systems (APAS) Division.

In the third quarter of 2005, we determined that we would have ongoing cash flows with an identifiable component of this operation. Accordingly, the results of operations for this component for all periods presented have been reclassified into continuing operations. The remaining robotic systems operations have been accounted for as discontinued operations for all periods presented. The amounts of this component that were included in continuing operations are as follows:

<b>(In thousands)</b>	<b>Three Months Ended</b>		<b>Nine Months Ended</b>	
	<b>October 1,</b>	<b>October 2,</b>	<b>October 1,</b>	<b>October 2,</b>
	<b>2005</b>	<b>2004</b>	<b>2005</b>	<b>2004</b>
Net sales	\$ 1,230	\$ 1,212	\$ 3,585	\$ 3,530
Income (loss) before income taxes	350	(56)	949	(393)

The net sales and loss before income taxes from the discontinued operations consisted of the following:

<b>(In thousands)</b>	<b>Three Months Ended</b>		<b>Nine Months Ended</b>	
	<b>October 1,</b>	<b>October 2,</b>	<b>October 1,</b>	<b>October 2,</b>
	<b>2005</b>	<b>2004</b>	<b>2005</b>	<b>2004</b>
Net sales	\$ 1,804	\$ 3,281	\$ 7,321	\$ 14,810
Loss before income taxes	(10,483)	(7,554)	(17,297)	(8,830)

In the third quarter of 2005, we recorded a \$9.2 million adjustment to reduce the carrying amount of the assets disposed to reflect the expected consideration for the sale, less estimated selling costs.

Unless otherwise indicated, Management's Discussion and Analysis of Financial Condition and Results of Operations excludes discontinued operations and relates only to continuing operations.

**Extraordinary Gain**

In March 2005, we settled a dispute arising out of our acquisition of Micro Robotics Systems, Inc. (MRSI). As a result of this settlement, we recorded an extraordinary gain of \$2.9 million in the first quarter of 2005. Pursuant to the terms of the settlement agreement, 114,691 shares of our common stock, which were being held in escrow, were returned to us and cancelled. Such shares had been issued to the former MRSI stockholders at the time of the acquisition of MRSI, or had been issued upon the exercise of options to purchase our common stock which had been granted at the time of the acquisition in connection with the assumption and conversion of options to purchase MRSI common stock. In

addition, outstanding options to purchase 21,606 shares of our common stock were cancelled and the exercise prices of all remaining outstanding and unexercised options which had been granted in connection with the MRSI acquisition were increased to reflect an adjustment to the total consideration paid for the acquisition.

### **Stockholders Equity Transactions**

In May 2005, we purchased an aggregate of 174,833 shares of our common stock at an average price of \$13.72 per share for a total of \$2.4 million. In June 2005, we purchased 3,220,300 shares of our common stock from Thermo Electron Corporation ( Thermo ) that we previously issued as part of the consideration for the acquisition of Spectra-Physics from Thermo in July 2004. We purchased the shares at a price of \$13.56 per share for a total of \$43.7 million. In August 2005, we received and cancelled 9,293 shares of common stock in payment of taxes owed on ordinary income recognized by certain employees upon vesting of shares of restricted stock issued to them under our 2001 Stock Incentive Plan. At the time, they were received, these shares had a value of \$13.71 per share for a total of \$0.1 million.

## **Table of Contents**

### **Critical Accounting Policies and Estimates**

Management's Discussion and Analysis of Financial Condition and Results of Operations is based on our consolidated financial statements included in this Quarterly Report on Form 10-Q, which have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and related disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. On an ongoing basis, we evaluate these estimates and assumptions, including those related to allowance for doubtful accounts, inventory reserves, warranty obligations, restructuring reserves, asset impairment valuations, pension liabilities and income tax valuations. We base these estimates on historical experience and on various other factors which we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. These estimates and assumptions by their nature involve risks and uncertainties, and may prove to be inaccurate. In the event that any of our estimates or assumptions are inaccurate in any material respect, it could have a material adverse effect on our reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.

The following critical accounting policies affect our more significant judgments and estimates used in the preparation of our consolidated financial statements.

### ***Revenue Recognition***

We recognize revenue after title to and risk of loss of products have passed to the customer (which typically occurs upon shipment from our facilities), or delivery of the service has been completed, provided that persuasive evidence of an arrangement exists, the fee is fixed or determinable and collectibility is probable. We recognize revenue and related costs for arrangements with multiple deliverables, such as equipment and installation, as each element is delivered or completed based upon its relative fair value, determined based upon the price that would be charged on a standalone basis. However, if a portion of the total contract price is not payable until installation is complete, we do not recognize such portion as revenue until completion of the installation; however, we record the full cost of the product at the time of shipment. We defer revenues for training until the service is completed. We recognize revenue for extended service contracts over the related contract periods.

Our customers generally have 30 days from the original invoice date (generally 60 days for international customers) to return a standard catalog product purchase for exchange or credit. Catalog products must be returned in the original condition and meet certain other criteria. Product returns of catalog items have historically been insignificant and are charged against revenue in the period returned. Custom, option-configured and certain other products as defined in the terms and conditions of sale cannot be returned. For certain non-catalog products, we establish a sales return reserve based on the historical product returns.

### ***Accounts and Notes Receivable***

We record reserves for specific receivables deemed to be at risk for collection, as well as a reserve based on our historical collections experience. We estimate the collectibility of customer receivables on an ongoing basis by reviewing past due invoices and assessing the current creditworthiness of each customer. A considerable amount of judgment is required in assessing the ultimate realization of these receivables. In the first quarter of 2005, we revised our method of estimating our reserve based upon our historical collections experience. As a result of this

## Edgar Filing: NEWPORT CORP - Form 10-Q

revision, our allowance for doubtful accounts was reduced by approximately \$0.7 million in the first quarter of 2005, which reduced *selling, general and administrative expense* for the nine months ended October 1, 2005 in the accompanying statement of operations.

Certain of our Japanese customers provide us with promissory notes on the due date of the receivable. The payment date of the promissory notes is generally 90 days from the original receivable due date. Subsequently, certain of these promissory notes are sold with recourse under line of credit agreements to one of four banks within Japan with which we do business. Such transactions are conducted in the ordinary course of business. For balance sheet

## **Table of Contents**

presentation purposes, amounts due to us under such promissory notes are reclassified from accounts receivable to current notes receivable. At October 1, 2005 and January 1, 2005, total promissory notes receivable amounted to \$4.4 million and \$6.9 million, respectively. The principal amount of promissory notes sold with recourse is included in both *notes receivable, net* and *short-term obligations* until the underlying note obligations are ultimately satisfied by payment by the customers to the banks. At October 1, 2005 and January 1, 2005, the principal amounts of such promissory notes included in *notes receivable, net* and *short-term obligations* were \$2.1 million and \$4.3 million, respectively.

### ***Pension Plans***

Several of our non-U.S. subsidiaries have defined benefit pension plans covering substantially all full-time employees at those subsidiaries. Some of the plans are unfunded, as permitted under the plans and applicable laws. For financial reporting purposes, the calculation of net periodic pension costs is based upon a number of actuarial assumptions, including a discount rate for plan obligations, an assumed rate of return on pension plan assets and an assumed rate of compensation increase for employees covered by the plan. All of these assumptions are based upon our judgment, considering all known trends and uncertainties. Actual results that differ from these assumptions would impact future expense recognition and the cash funding requirements of our pension plans.

### ***Inventories***

We state our inventories at the lower of cost (determined on either a first in, first-out [FIFO] or average cost basis) or fair market value and include materials, labor and manufacturing overhead. We write down excess and obsolete inventory to net realizable value. In assessing the ultimate realization of inventories, we make judgments as to future demand requirements and compare those requirements with the current or committed inventory levels. We record any amounts required to reduce the carrying value of inventory to net realizable value as a charge to cost of sales.

### ***Warranty***

Unless otherwise stated in our product literature or in our agreements with our customers, products sold by our Photonics and Precision Technologies Division generally carry a one-year warranty from the original invoice date on all product material and workmanship. Products of such division sold to original equipment manufacturer (OEM) customers generally carry longer warranties, typically 15 to 24 months. Products sold by our Lasers Division generally carry warranties that vary by product and product component, but generally range from 90 days to two years. In certain cases, warranties for Lasers Division products are limited by either a set calendar period or a maximum amount of usage of the product, whichever occurs first. Defective products will be either repaired or replaced, generally at our option, upon meeting certain criteria. We accrue a provision (based on historical experience) for the estimated costs that may be incurred for product warranties relating to a product as a component of cost of sales at the time revenue for that product is recognized. While we engage in extensive product quality programs and processes, including actively monitoring and evaluating the quality of our component suppliers, our warranty obligations are affected by product failure rates, material usage and service delivery costs incurred in correcting a product failure. Should actual product failure rates, material usage and/or service delivery costs differ from our estimates, revisions to the estimated warranty obligation would be required which could adversely affect our operating results.

### ***Impairment of Assets***

## Edgar Filing: NEWPORT CORP - Form 10-Q

We assess the impairment of long-lived assets whenever events or changes in circumstances indicate that their carrying value may not be recoverable. The determination of related estimated useful lives and whether or not these assets are impaired involves significant judgments, related primarily to the future profitability and/or future value of the assets. Changes in our strategic plan and/or market conditions could significantly impact these judgments and could require adjustments to recorded asset balances. We hold minority interests in companies having operations or technologies in areas which are within or adjacent to our strategic focus when acquired, all of which are privately held and whose values are difficult to determine. We record an investment impairment charge in any reporting period where we believe an investment has experienced a decline in value that is other than temporary. Future changes in our strategic direction, adverse changes in market conditions or poor operating results of underlying



## **Table of Contents**

investments could result in losses or an inability to recover the carrying value of the investments that may not be reflected in an investment's current carrying value, thereby possibly requiring an impairment charge in the future.

We perform annual impairment tests of our goodwill and other intangible assets in accordance with SFAS No. 142, *Goodwill and Other Intangible Assets*. Under SFAS No. 142, goodwill is no longer amortized but is subject to impairment tests based upon a comparison of the fair value of each of our reporting units, as defined, and the carrying value of the reporting units' net assets, including goodwill. SFAS No. 142 requires a review of goodwill and other intangible assets for impairment at least annually or when circumstances exist that would indicate an impairment of such goodwill or other intangible assets. We perform the annual impairment review as of the beginning of the fourth quarter of each year.

## ***Income Taxes***

We provide for income taxes in interim periods based on the estimated effective income tax rate for the complete fiscal year. The income tax provision is computed on the pretax income of the consolidated entities located within each taxing jurisdiction based on current tax law. Deferred taxes result from the future tax consequences associated with temporary differences between the recorded amounts of the assets and liabilities for tax and financial accounting purposes. A valuation allowance for deferred tax assets is recorded to the extent we cannot determine, in accordance with the provisions of SFAS No. 109, *Accounting for Income Taxes*, that the ultimate realization of the net deferred tax assets is more likely than not.

We currently have significant deferred tax assets, which are subject to periodic recoverability assessments. We recorded a valuation reserve in the third quarter of 2002 against our deferred tax assets pursuant to SFAS No. 109, due to the uncertainty as to the timing and ultimate realization of those assets. As such, we did not recognize any tax benefit on the losses recorded in 2004 and recorded a valuation allowance against deferred tax assets for the first nine months of 2005. For the foreseeable future, the Federal tax provision related to future earnings will be substantially offset by a reduction in the valuation reserve, and pretax losses will not be offset by a tax benefit due to the uncertainty of the recoverability of the deferred tax assets. Accordingly, tax expense will consist primarily of certain required state income taxes and taxes in certain foreign jurisdictions.

Realization of our deferred tax assets is principally dependent upon our achievement of future taxable income, the estimation of which requires significant management judgment. Our judgments regarding future profitability may change due to many factors, including future market conditions and our ability to successfully execute our business plans and/or tax planning strategies. These changes, if any, may require material adjustments to these deferred tax asset balances.

We are subject to audit by federal, state or foreign tax authorities in the ordinary course of business. These audits include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal, state and local tax laws. In evaluating the exposure associated with various tax filing positions, we often accrue charges for probable exposures. During 2004, we concluded a number of tax examinations with favorable results. Therefore, during the annual evaluation of tax positions for 2004, we decreased the amount previously accrued for probable exposures. At October 1, 2005, we believe that we have appropriately accrued for probable exposures. To the extent we were to prevail in matters for which accruals have been established or be required to pay amounts in excess of reserves, our effective tax rate in a given financial statement period could be materially affected.

## **Accrued Restructuring Costs**

***2004 Restructuring Plan***

In connection with the acquisition of Spectra-Physics, we approved a preliminary restructuring plan to consolidate certain locations, which included \$2.2 million for employee relocation and employee severance and related termination costs and \$3.2 million in costs related to facility consolidations. In the third quarter of 2005, we finalized this plan, which included \$3.3 million for employee relocation and employee severance and related termination costs and \$2.2 million related to facility consolidation costs, resulting in a net increase of approximately

**Table of Contents**

\$0.1 million from the preliminary plan. This increase resulted in an adjustment to goodwill of approximately \$0.1 million.

The following table summarizes the activity in the accrued restructuring costs related to the purchase of Spectra-Physics, which primarily involve the payment of cash:

<u>(In thousands)</u>	<b>Employee</b>		<b>Total</b>
	<b>Relocation and Severance</b>	<b>Facility Consolidation</b>	
Accrued restructuring at January 1, 2005	\$ 1,687	\$ 3,186	\$ 4,873
Cash payments	(2,124)	(252)	(2,376)
Adjustments to restructuring plan	1,095	(971)	124
Accrued restructuring at October 1, 2005	\$ 658	\$ 1,963	\$ 2,621

The facility consolidation costs will be paid over the term of the lease for the closed facility, which expires in 2011. At October 1, 2005 and January 1, 2005, \$1.0 million and \$2.1 million, respectively, of these accrued restructuring costs were expected to be paid within one year and were included in current liabilities in *accrued restructuring costs*, and \$1.6 million and \$2.8 million, respectively, of accrued restructuring costs were included in long-term liabilities in *accrued restructuring costs and other liabilities*, in the accompanying consolidated balance sheets.

**2002 Restructuring Plan**

During 2002, in response to the continued severe downturn in the fiber optic communications market and the uncertainty with respect to the pace of recovery in the semiconductor equipment market, our Board of Directors approved a restructuring and cost reduction plan designed to bring our operating costs in line with our business outlook at that time. In the third quarter of 2005, we increased our estimate of the required liability for facility consolidations by \$0.1 million to reflect revised estimates of reduced future sublease income.

The following table summarizes the activity in accrued restructuring costs related to the 2002 restructuring plan:

<u>(In thousands)</u>	<b>Facility Consolidation</b>
Accrued restructuring at January 1, 2005	\$ 833
Cash payments	(311)
Adjustments to restructuring plan	135
Accrued restructuring at October 1, 2005	\$ 657

## Edgar Filing: NEWPORT CORP - Form 10-Q

As of October 1, 2005, \$0.7 million of facility-related costs remained accrued for under the Company's 2002 restructuring plan. The facility consolidation reserves will be paid over the associated lease terms, which expire at various dates between 2006 and 2008. At October 1, 2005 and January 1, 2005, \$0.5 million and \$0.6 million, respectively, of accrued restructuring costs were expected to be paid within one year and were included in current liabilities in *accrued restructuring costs*, and \$0.2 million of accrued restructuring costs were included in long-term liabilities in *accrued restructuring costs and other liabilities* for both periods, in the accompanying consolidated balance sheets.

**Table of Contents****Results of Operations for the Three and Nine Months Ended October 1, 2005 and October 2, 2004**

The following table represents the results of operations for the periods indicated as a percentage of net sales:

	Percentage of Net Sales		Percentage of Net Sales	
	Three Months Ended		Nine Months Ended	
	October 1,	October 2,	October 1,	October 2,
	2005	2004	2005	2004
Net sales	100.0%	100.0%	100.0%	100.0%
Cost of sales	57.6	69.1	58.3	67.1
Gross profit	42.4	30.9	41.7	32.9
Selling, general and administrative expense	25.2	29.7	25.4	27.2
Research and development expense	8.8	8.2	8.9	8.0
Operating income (loss)	8.4	(7.0)	7.4	(2.3)
Interest and other expense, net	(0.7)	(4.1)	(0.6)	(0.7)
Income (loss) from continuing operations before income taxes	7.7	(11.1)	6.8	(3.0)
Income tax provision	1.1	1.0	1.0	0.5
Income (loss) from continuing operations before extraordinary gain	6.6	(12.1)	5.8	(3.5)
Loss from discontinued operations, net of income taxes	(8.9)	(8.4)	(5.1)	(5.2)
Extraordinary gain on settlement of litigation			1.0	
Net income (loss)	(2.3)%	(20.5)%	1.7%	(8.7)%

***Net Sales***

Net sales for the quarter ended October 1, 2005 were \$103.0 million, an increase of \$12.6 million, or 13.9%, compared with the corresponding period of 2004. Net sales for the nine months ended October 1, 2005 were \$299.9 million, an increase of \$131.2 million, or 77.8%, compared with the corresponding period of 2004.

The net sales increase of \$12.6 million in the third quarter of 2005 compared with the same period of 2004 was due primarily to stronger overall market conditions in the microelectronics and scientific research, aerospace and defense/security markets, offset in part by reduced sales to life and health sciences customers. Our sales to the microelectronics market in the 2005 period included \$8.1 million in sales to a computer

## Edgar Filing: NEWPORT CORP - Form 10-Q

peripherals manufacturer of automated systems used in its manufacturing process. This increase was also due to the inclusion of a complete quarter of Spectra-Physics sales in our results of operations for the third quarter of 2005, compared with the third quarter of 2004, which only included Spectra-Physics sales from the date of acquisition on July 16, 2004.

The net sales increase of \$131.2 million in the first nine months of 2005 compared with the same period of 2004 was due primarily to the inclusion of a full nine months of sales by our Spectra-Physics businesses in 2005. Spectra-Physics contributed \$169.0 million in the first nine months of 2005, an increase of \$118.8 million compared with the comparable period of 2004, which only included Spectra-Physics sales from the date of acquisition on July 16, 2004. In addition, net sales by our existing businesses increased by a total of \$12.4 million, or 10.5%, in the first nine months of 2005 compared with the same period of 2004, due primarily to higher sales to a computer peripherals manufacturer of automated systems used in its manufacturing process, as well as stronger overall sales to other microelectronics customers.

Net sales to the scientific research, aerospace and defense/security markets in the quarter ended October 1, 2005 were \$38.9 million, an increase of \$4.6 million, or 13.4%, compared with the same period of 2004. This increase was due primarily to stronger sales of laser products to these markets, and to the inclusion of a complete quarter of

---

**Table of Contents**

Spectra-Physics sales for the third quarter of 2005, offset in part by decreases in sales to these markets by our existing businesses. Our net sales to these markets for the nine months ended October 1, 2005 totaled \$115.7 million, an increase of \$53.6 million, or 86.3%, compared with the same period of 2004. The increase in sales to these markets in the nine months ended October 1, 2005 was due primarily to the inclusion of a full nine months of sales by our Spectra-Physics businesses. Spectra-Physics contributed \$72.9 million in sales to these markets in the first nine months of 2005, an increase of \$53.5 million compared with the first nine months of 2004, which only included Spectra-Physics sales from the date of acquisition on July 16, 2004. Net sales of our existing businesses for the nine months ended October 1, 2005 were flat compared with the same period in 2004.

Net sales to the microelectronics market for the three months ended October 1, 2005 were \$34.0 million, an increase of \$8.7 million, or 34.4%, compared with the same period of 2004. The increase in the third quarter of 2005 was due primarily to a sales increase of \$8.5 million to this market by our existing businesses, and to the inclusion of a complete quarter of Spectra-Physics sales for the third quarter of 2005. Our net sales to this market for the nine months ended October 1, 2005 totaled \$86.5 million, an increase of \$32.6 million, or 60.5%, compared with the same period of 2004. The increase in the nine months ended October 1, 2005 compared with the prior year period was due primarily to the inclusion of a full nine months of sales by our Spectra-Physics businesses. Spectra-Physics contributed \$34.2 million in sales to this market in the first nine months of 2005, an increase of \$22.8 million compared with the first nine months of 2004, which only included Spectra-Physics sales from the date of acquisition on July 16, 2004. In addition, our existing businesses saw increases in sales to this market totaling \$9.8 million compared with the prior year period. The increases in our existing businesses for both periods were due primarily to a large sale to a computer peripherals manufacturer of automated systems used in its manufacturing process, offset in part by continued significantly reduced demand by semiconductor manufacturers for capital equipment on a year-over-year basis as a result of the cyclical downturn in this market.

Net sales to the life and health sciences market for the three months ended October 1, 2005 were \$13.6 million, a decrease of \$2.1 million, or 13.4%, compared with the same period of 2004. The decrease in the third quarter of 2005 compared with the prior year period was due primarily to the timing of shipments of products to customers in this market. Our net sales to this market for the nine months ended October 1, 2005 totaled \$46.5 million, an increase of \$23.0 million, or 97.9%, compared with the same period of 2004. The increase in the nine months ended October 1, 2005 was due primarily to the inclusion of a full nine months of sales by our Spectra-Physics businesses. Spectra-Physics contributed \$33.6 million in sales to this market in the first nine months of 2005, an increase of \$22.4 million compared with the first nine months of 2004, which only included Spectra-Physics sales from the date of acquisition on July 16, 2004.

Net sales to our other end markets for the three months ended October 1, 2005 were \$16.5 million, an increase of \$1.4 million, or 9.3%, compared with the same period of 2004. These increases were due primarily to higher sales to this market of photonics component products in the third quarter of 2005, which included a full quarter of sales by our Spectra-Physics businesses compared with the 2004 period. Our net sales to these markets for the nine months ended October 1, 2005 totaled \$51.2 million, an increase of \$22.0 million, or 75.3%, compared with the same period of 2004. The increase in the nine month period was due primarily to the inclusion of a full nine months of sales by our Spectra-Physics businesses. Spectra-Physics contributed \$28.3 million in sales to this market in the first nine months of 2005, an increase of \$20.1 million compared with the first nine months of 2004, which only included Spectra-Physics sales from the date of acquisition on July 16, 2004. In addition, in the nine months ended October 1, 2005, our existing businesses saw increases in sales to these markets totaling \$1.9 million, or 9.0%, due primarily to strong overall market conditions.

**Table of Contents**

Domestic and international sales by end market were as follows:

<b>Domestic Sales:</b>	<b>Three Months Ended</b>			<b>Percentage Increase</b>
	<b>October 1,</b>	<b>October 2,</b>	<b>Increase</b>	
	<b>2005</b>	<b>2004</b>		
<b>(In thousands)</b>				
Scientific research, aerospace and defense/security	\$ 19,333	\$ 18,221	\$ 1,112	6.1%
Microelectronics	19,928	19,104	824	4.3
Life and health sciences	8,317	10,120	(1,803)	(17.8)
Other end markets	6,429	4,572	1,857	40.6
	<b>\$ 54,007</b>	<b>\$ 52,017</b>	<b>\$ 1,990</b>	<b>3.8%</b>

<b>International Sales:</b>	<b>Three Months Ended</b>			<b>Percentage Increase</b>
	<b>October 1,</b>	<b>October 2,</b>	<b>Increase</b>	
	<b>2005</b>	<b>2004</b>		
<b>(In thousands)</b>				
Scientific research, aerospace and defense/security	\$ 19,519	\$ 16,061	\$ 3,458	21.5%
Microelectronics	14,037	6,140	7,897	128.6
Life and health sciences	5,324	5,612	(288)	(5.1)
Other end markets	10,118	10,524	(406)	(3.9)
	<b>\$ 48,998</b>	<b>\$ 38,337</b>	<b>\$ 10,661</b>	<b>27.8%</b>

<b>Domestic Sales:</b>	<b>Nine Months Ended</b>			<b>Percentage Increase</b>
	<b>October 1,</b>	<b>October 2,</b>	<b>Increase</b>	
	<b>2005</b>	<b>2004</b>		
<b>(In thousands)</b>				
Scientific research, aerospace and defense/security	\$ 55,169	\$ 33,744	\$ 21,425	63.5%
Microelectronics	58,380	45,837	12,543	27.4
Life and health sciences	27,632	16,951	10,681	63.0
Other end markets	18,576	11,391	7,185	63.1
	<b>\$ 159,757</b>	<b>\$ 107,923</b>	<b>\$ 51,834</b>	<b>48.0%</b>

<b>International Sales:</b>	<b>Nine Months Ended</b>			<b>Percentage Increase</b>
	<b>October 1,</b>	<b>October 2,</b>	<b>Increase</b>	
	<b>(In thousands)</b>			



Edgar Filing: NEWPORT CORP - Form 10-Q

	<u>2005</u>	<u>2004</u>	<u></u>	<u>Increase</u>
Scientific research, aerospace and defense/security	\$ 60,545	\$ 28,370	\$ 32,175	113.4%
Microelectronics	28,111	8,103	20,008	246.9
Life and health sciences	18,853	6,491	12,362	190.4
Other end markets	32,605	17,837	14,768	82.8
	<u>\$ 140,114</u>	<u>\$ 60,801</u>	<u>\$ 79,313</u>	<u>130.4%</u>

**Table of Contents**

Geographically, net sales to international customers were as follows:

<b>(In thousands)</b>	<b>Three Months Ended</b>			<b>Percentage</b>
	<b>October 1,</b>	<b>October 2,</b>		
	<b>2005</b>	<b>2004</b>	<b>Increase</b>	<b>Increase</b>
Europe	\$ 19,794	\$ 18,347	\$ 1,447	7.9%
Pacific Rim	24,049	15,792	8,257	52.3
Other	5,155	4,198	957	22.8
	<b>\$ 48,998</b>	<b>\$ 38,337</b>	<b>\$ 10,661</b>	<b>27.8%</b>

<b>(In thousands)</b>	<b>Nine Months Ended</b>			<b>Percentage</b>
	<b>October 1,</b>	<b>October 2,</b>		
	<b>2005</b>	<b>2004</b>	<b>Increase</b>	<b>Increase</b>
Europe	\$ 63,485	\$ 31,885	\$ 31,600	99.1%
Pacific Rim	61,931	21,933	39,998	182.4
Other	14,698	6,983	7,715	110.5
	<b>\$ 140,114</b>	<b>\$ 60,801</b>	<b>\$ 79,313</b>	<b>130.4%</b>

The increase in sales to international customers for the third quarter of 2005 was due primarily to higher sales to a computer peripherals manufacturer of automated systems used in its manufacturing process, as well as stronger overall sales in the scientific research, aerospace and defense/security markets. In addition, international sales by our Spectra-Physics businesses increased by \$2.1 million compared with the third quarter of 2004. The increase in sales to international customers for the nine months ended October 1, 2005 was due primarily to the inclusion of a full nine months of sales by our Spectra-Physics businesses. Spectra-Physics contributed \$88.8 million in international sales in the first nine months of 2005, an increase of \$62.2 million compared with the first nine months of 2004, which only included Spectra-Physics sales from the date of acquisition on July 16, 2004. In addition, our existing businesses saw international sales increases for the nine months ended October 1, 2005 totaling \$17.1 million, or 50.0%, compared with the corresponding 2004 period. This increase was also due primarily to the higher sales to a computer peripherals manufacturer as discussed above.

The results of our international operations are subject to currency fluctuations. As the value of the U.S. dollar weakens relative to other currencies, sales in those currencies convert to more U.S. dollars; conversely, when the value of the U.S. dollar strengthens relative to other currencies, sales in those countries convert to fewer U.S. dollars. Currency fluctuations did not have a material impact on our results for the three months or nine months ended October 1, 2005 compared with the corresponding 2004 periods.

We expect our net sales in the fourth quarter of 2005 to be slightly higher than the third quarter level. However, our business is subject to risks arising from market conditions in our primary end markets, as well as from general economic conditions.

## Edgar Filing: NEWPORT CORP - Form 10-Q

We expect that our sales to the scientific research, aerospace and defense/security markets will increase in the fourth quarter of 2005 compared with the third quarter of 2005. Overall, we expect that our sales to these markets will fluctuate from period to period in line with changes in overall research and defense spending levels, but will increase over time as we increase our penetration of these markets.

We expect our sales to the microelectronics market to be flat to slightly higher in the fourth quarter of 2005 compared with the third quarter of 2005. Overall, we expect our sales to this market to fluctuate from period to period, due primarily to cyclical changes in the levels of capital spending by semiconductor manufacturers.

We expect our sales to the life and health sciences market for the fourth quarter of 2005 to be slightly higher compared with the third quarter of 2005. In general, we expect our sales to this market to fluctuate on a quarter to quarter basis in the short term due to our concentration of significant OEM customers in this market, but to increase over time as we increase our penetration of this market.

## **Table of Contents**

### ***Gross Margin***

Gross margin was 42.4% and 30.9% for the three months ended October 1, 2005 and October 2, 2004, respectively, and 41.7% and 32.9% for the nine months ended October 1, 2005 and October 2, 2004, respectively. Gross margin for both the three and nine month periods in 2005 was positively impacted compared with the same periods in 2004 due to the higher absorption of fixed overhead resulting from the increased sales levels, and to the benefits from the divestiture of our low-margin manufacturing operations in Oroville, California, which we completed early in the third quarter of 2005.

In addition, gross margin for the three and nine months ended October 2, 2004 was negatively impacted by charges we recorded in both periods to cost of sales for acquisition, integration and other items. These charges did not recur in the comparable 2005 periods. These charges included a charge of \$6.7 million related to the sale of acquired inventory that had been written up to an amount that included a normal selling margin in accordance with SFAS No. 141, *Business Combinations*, and sold during the third quarter of 2004, and an impairment charge of \$1.5 million for an intellectual property intangible asset that we previously purchased from a third party, and we deemed to be non-strategic as a result of the acquisition of Spectra-Physics.

We expect our gross margin in the fourth quarter of 2005 to be slightly higher than the third quarter of 2005 due to the higher expected sales levels and increased manufacturing efficiencies resulting from our integration actions.

### ***Selling, General and Administrative (SG&A) Expense***

SG&A expense totaled \$26.0 million, or 25.2% of net sales, and \$26.9 million, or 29.7% of net sales, for the three months ended October 1, 2005 and October 2, 2004, respectively. In the three months ended October 1, 2005, SG&A expense decreased by \$0.9 million, or 3.3%, compared with the same period in 2004. SG&A expense in the third quarter of 2004 included approximately \$2.9 million in acquisition, integration and restructuring charges that did not recur in 2005. This decrease was offset in part by approximately \$1.9 million of increased SG&A expense resulting from the inclusion of Spectra-Physics businesses for a complete quarter, compared with the third quarter of 2004, which only included SG&A expense for Spectra-Physics from the acquisition date of July 16, 2004.

SG&A expense for the nine months ended October 1, 2005 and October 2, 2004 totaled \$76.2 million, or 25.4% of net sales, and \$45.9 million, or 27.2% of net sales, respectively, an increase of \$30.3 million. Approximately \$25.9 million of this increase was attributable to the inclusion of a full nine months of Spectra-Physics SG&A expense for which there were no comparable amounts in 2004 prior to the July 16, 2004 acquisition date. The remainder of this increase was attributable primarily to an increase in variable selling expenses and incentive compensation associated with higher sales volume, the amortization of acquired intangible assets related to the Spectra-Physics acquisition, and increased accounting, auditing and tax services fees due to our increased size and compliance with Section 404 of the Sarbanes-Oxley Act for Spectra-Physics.

We expect that SG&A expense will be slightly higher in the fourth quarter of 2005 compared with the third quarter of 2005. In general, we expect that SG&A expense will vary as a percentage of sales in the future on an inverse basis with our sales level in any given period. Because the majority of our SG&A expense is fixed in the short term, these fluctuations will likely not be in proportion to the changes in net sales.

### ***Research and Development (R&D) Expense***

## Edgar Filing: NEWPORT CORP - Form 10-Q

R&D expense totaled \$9.1 million, or 8.8% of net sales, and \$7.4 million, or 8.2% of net sales, for the three months ended October 1, 2005 and October 2, 2004, respectively. The year-over-year increase of \$1.7 million, or 23.0%, was due primarily to our continued strategic investment in R&D.

R&D expense totaled \$26.7 million, or 8.9% of net sales, and \$13.4 million, or 8.0% net sales, for the nine months ended October 1, 2005 and October 2, 2004, respectively. Approximately \$11.9 million of this \$13.3 million year-over-year increase was attributable to the inclusion of a full nine months of Spectra-Physics R&D expense for which there were no comparable amounts in 2004 prior to the July 16, 2004 acquisition date.

## **Table of Contents**

We expect that R&D expense in the fourth quarter of 2005 will be slightly higher than the third quarter level. We believe that the continued development and advancement of our key products and technologies is critical to our future success, and we intend to continue to invest in key R&D initiatives, while working to ensure that the efforts are focused and the funds are deployed efficiently. In general, we expect that R&D expense as a percentage of net sales will vary in the future on an inverse basis with our sales level in any given period. Because of our commitment to continued product development, and because the majority of our R&D expense is fixed in the short term, these fluctuations will likely not be in proportion to the changes in net sales.

### ***Interest and Other Expense, Net***

Interest and other expense, net for the three and nine months ended October 1, 2005 totaled \$0.7 million and \$1.9 million, respectively. Interest and other expense, net for the three and nine months ended October 2, 2004 totaled \$3.7 million and \$1.2 million, respectively. For the three month period, the year-over-year decrease was due primarily to the negative impact of charges recorded in the third quarter of 2004, including a charge of \$1.7 million for losses on sale of marketable securities prior to their maturity in order to fund the cash portion of the purchase price for the Spectra-Physics acquisition, and a charge of \$1.4 million for the loss on a minority interest investment that incurred an other-than-temporary reduction in value.

In addition to the items noted above, for the nine months ended October 1, 2005, we recorded higher interest expense compared with the prior year period, due primarily to interest expense on the debt we issued in connection with the acquisition of Spectra-Physics in July 2004, and interest expense on lines of credit we assumed in connection with the acquisition. Also, as a result of cash paid in connection with the acquisition, our average cash and marketable securities balances were significantly lower during the nine months ended October 1, 2005 compared with the prior year periods, resulting in lower interest income earned. In addition, due to rising interest rates, we realized lower gains on sales of marketable securities during the 2005 period and our portfolio shifted to a net unrealized loss position.

We expect to incur interest and other expense, net in future periods, due primarily to interest expense incurred on short-term and long-term debt, offset in part by interest earned on cash and marketable securities. In the first nine months of 2005, we used \$46.2 million to purchase shares of our common stock. As a result, we expect interest income in future periods to be lower due to our lower cash balances. The overall level of such interest income will fluctuate period to period based on our cash balances and market interest rates.

### ***Income Taxes***

The effective tax rate from continuing operations for the three and nine months ended October 1, 2005 was an expense of 13.9% and 14.7%, respectively, compared with an expense of 9.3% and 15.2% in the corresponding prior year periods. We have recorded a valuation reserve against our deferred tax assets pursuant to SFAS No. 109 due to the uncertainty as to the timing and ultimate realization of those assets. As a result, for the foreseeable future, the Federal tax provision related to future earnings will be substantially offset by a reduction in the valuation reserve, and pretax losses will not be offset by a tax benefit due to the uncertainty of the recoverability of the deferred tax assets. Accordingly, tax expense will consist primarily of certain required state income taxes and taxes in certain foreign jurisdictions.

Overall, we expect our tax rate in the fourth quarter of 2005 to be slightly higher than the tax rate in the third quarter of 2005.

### **Liquidity and Capital Resources**

Net cash provided by our operating activities of \$3.5 million for the nine months ended October 1, 2005 was attributable primarily to cash provided by our results of operations, offset in part by an increase in accounts and notes receivable as a result of higher sales at the end of the third quarter, an increase in inventory and a decrease in accrued expenses (including incentive compensation and restructuring costs) due primarily to the timing of payments.

---

**Table of Contents**

Net cash provided by investing activities of \$30.4 million for the nine months ended October 1, 2005 consisted of net proceeds from the sale of marketable securities of \$34.8 million and proceeds of \$1.8 million from the sale of businesses and equity investments, offset in part by net purchases of property and equipment of \$6.2 million.

Net cash used in financing activities of \$41.3 million for the nine months ended October 1, 2005 consisted of payments totaling \$46.2 million to purchase shares of our common stock as discussed below and payments of \$0.2 million for capital lease obligations, offset in part by proceeds of \$4.3 million received from the issuance of common stock in connection with stock option and employee stock purchase plans, and short-term borrowings of \$0.8 million.

At October 1, 2005, we had cash and cash equivalents of \$32.4 million and marketable securities of \$30.9 million. The majority of these securities are invested in one portfolio managed by a professional investment management firm, under the oversight of our senior financial management team. This portfolio manager invests the funds allocated in accordance with our Investment Policy, which is reviewed regularly by our senior financial management and the Audit Committee of our Board of Directors. We expect that our cash balances will fluctuate in the future based on factors such as cash used in or provided by ongoing operations, acquisitions or divestitures, investments in other companies, share repurchases, capital expenditures and contractual obligations, and changes in interest rates.

At October 1, 2005, we had a total of seven lines of credit, including one domestic revolving line of credit, two revolving lines of credit with Japanese banks, and four other lines of credit with Japanese banks, which are used to sell trade notes receivable with recourse to the banks.

Our domestic revolving line of credit has a total credit limit of \$5.0 million and expires December 1, 2005. Certain of the marketable securities that are being managed by the lending institution collateralize the line of credit. The line bears interest at the prevailing prime rate, or the prevailing London Interbank Offered Rate (3.87% at October 1, 2005) plus 1.5%, at our option, and an unused line fee of 0.25% per year. At October 1, 2005, there were no balances outstanding under the line of credit, with \$1.8 million available under the line, after considering outstanding letters of credit totaling \$3.2 million.

The two revolving lines of credit with Japanese banks total 1.7 billion yen (\$15.0 million at October 1, 2005) and expire as follows: \$7.1 million on November 30, 2005, \$5.3 million on March 18, 2006 and \$2.6 million on June 30, 2008. The lines are not secured and bear interest at the prevailing bank rate. At October 1, 2005, we had \$12.4 million outstanding and no amounts available for borrowing under these lines of credit. Approximately \$9.8 million of the amount outstanding under these revolving lines of credit at October 1, 2005 was included in *short-term obligations* in the accompanying balance sheet, and approximately \$2.6 million was included in *long-term debt* as the due date of this portion of the outstanding borrowings is June 30, 2008.

The four other lines of credit with Japanese banks, which are used to sell notes receivable with recourse, total 800 million yen (\$7.1 million at October 1, 2005), have no expiration date and bear interest at the bank's prevailing rate. At October 1, 2005, we had \$2.1 million outstanding and \$5.0 million available for the sale of notes receivable under these lines of credit. The weighted average interest rate on all borrowings on all six Japanese lines of credit as of October 1, 2005 was 1.5%.

In April 2003, our Board of Directors approved a share repurchase program, authorizing the purchase of up to 3.9 million shares, or 10% of our then-outstanding stock. In May 2005, we purchased 174,833 shares of our common stock in the open market at an average price of \$13.72 per share for a total of \$2.4 million. In June 2005, we purchased 3,220,300 shares of our common stock from Thermo that we previously issued to Thermo as part of the consideration for the acquisition of Spectra-Physics in July 2004. We purchased the shares at a price of \$13.56 per share for a total of \$43.7 million. As of October 1, 2005, 219,038 shares remain available for purchase under the share repurchase program. The



## Edgar Filing: NEWPORT CORP - Form 10-Q

timing and amount of any future purchases will depend on factors including our share price, cash balances, expected cash requirements and general business and market conditions.

In August 2005, we received and cancelled 9,293 shares of common stock in payment of taxes owed on ordinary income recognized by certain employees upon the vesting of shares of restricted stock issued to them under our 2001 Stock Incentive Plan. At the time they were received, these shares had a value of \$13.71 per share for a total of \$0.1 million.

Page 30

---

## **Table of Contents**

We believe our current working capital position, together with our expected future cash flows from operations will be adequate to fund our operations in the ordinary course of business, anticipated capital expenditures, debt payment requirements and other contractual obligations for the foreseeable future. However, this belief is based upon many assumptions and is subject to numerous risks (see *Risks Relating To Our Business*, on pages 32-41), and there can be no assurance that we will not require additional funding in the future.

We have no present agreements or commitments with respect to any material acquisitions of other businesses, products, product rights or technologies or any material capital expenditures. However, we will continue to evaluate acquisitions of and/or investments in products, technologies, capital equipment or improvements or companies that complement our business and may make such acquisitions and/or investments in the future. Accordingly, there can be no assurance that we will not need to obtain additional sources of capital in the future to finance any such potential acquisitions and/or investments. We cannot assure you that any such financing would be available, or that, if available, such financing would be obtainable on terms favorable to us and would not be dilutive.

## **Recent Accounting Pronouncements**

In December 2004, the Financial Accounting Standards Board (FASB) issued SFAS No. 123R, *Share-Based Payment*. SFAS No. 123R requires employee stock options and rights to purchase shares under stock participation plans to be accounted for under the fair value method, and eliminates the ability to account for these instruments under the intrinsic value method prescribed by APB Opinion No. 25, and allowed under the original provisions of SFAS No. 123. SFAS No. 123R requires the use of an option pricing model for estimating fair value, which is amortized to expense over the period in which the related employee services are rendered. We are currently assessing the impact that the adoption of SFAS No. 123R will have on our consolidated results of operations. Although the assessment is ongoing, management believes that the impact of the adoption of SFAS No. 123R will be material to our consolidated results of operations, but that it will have no impact on our overall financial position. If we had applied the provisions of SFAS No. 123R to the financial statements for the three and nine months ended October 1, 2005, our net loss for the three months ended October 1, 2005 would have been increased by approximately \$2.1 million, and our net income for the nine months ended October 1, 2005 would have been reduced by approximately \$5.6 million. However, due to the alternative option pricing models and assumptions, the lower numbers of options granted in recent years, and the lower valuations of such options compared with options granted previously, this figure may not be representative of the impact on our future results of operations. In April 2005, the Securities and Exchange Commission issued Release 33-8568, which delayed the effective date to fiscal years beginning after June 15, 2005. SFAS No. 123R allows for either prospective recognition of compensation expense or retrospective recognition. The retrospective method would be applied to all prior years in which SFAS No. 123 was effective. We are currently evaluating these transition methods.

In November 2004, the FASB issued SFAS No. 151, *Inventory Costs - An Amendment of ARB No. 43, Chapter 4*. SFAS No. 151 clarifies that abnormal amounts of idle facility expense, freight, handling costs and spoilage should be expensed as incurred and not included in overhead. Further, SFAS No. 151 requires that allocation of fixed and production facilities overhead to conversion costs should be based on normal capacity of the production facilities. The provisions in SFAS No. 151 are effective for inventory costs incurred during fiscal years beginning after June 15, 2005. We are currently evaluating the impact of the adoption of this standard, but do not believe that the adoption of SFAS No. 151 will have a significant effect on our results of operations or financial position.

In March 2004, the FASB approved the consensus reached on the Emerging Issues Task Force (EITF) Issue No. 03-1, *The Meaning of Other-Than-Temporary Impairment and Its Application to Certain Investments*. It provides guidance for identifying other-than-temporarily impaired investments. EITF 03-1 also provides new disclosure requirements for investments that are deemed to be temporarily impaired. In September 2004, the FASB issued a FASB Staff Position (FSP) EITF 03-1-1 that delays the effective date of the measurement and recognition guidance in EITF 03-1 until further notice. The disclosure requirements of EITF 03-1 are effective for fiscal years ending after December 15, 2003 and are reflected in our Annual Report on Form 10-K for the year ended January 1, 2005. After the FASB reaches a final decision on the measurement and recognition provisions, we will evaluate the impact of the adoption of the accounting provisions of EITF 03-1.



**Table of Contents**

**RISKS RELATING TO OUR BUSINESS**

*The following is a summary of certain risks we face in our business. They are not the only risks we face. Additional risks of which we are not presently aware or that we currently believe are immaterial may also harm our business and results of operations. The trading price of our common stock could decline due to the occurrence of any of these risks, and investors could lose all or part of their investment. In assessing these risks, investors should also refer to the other information contained or incorporated by reference in our other filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended January 1, 2005 and in this Quarterly Report on Form 10-Q, including our consolidated financial statements and related notes included therein and herein.*

**Our operating results are difficult to predict, and if we fail to meet the expectations of investors and/or securities analysts, the market price of our common stock will likely decline significantly.**

Our operating results in any given quarter have fluctuated and will likely continue to fluctuate. These fluctuations are typically unpredictable and can result from numerous factors including:

fluctuations in our customers' capital spending, industry cyclicality (particularly in the semiconductor industry), levels of government funding available to our customers, and other economic conditions within the markets we serve;

demand for our products and the products sold by our customers;

the level of orders within a given quarter and preceding quarters;

the timing and level of cancellations and delays of orders for our products;

the timing of product shipments within a given quarter;

our timing in introducing new products;

variations in the mix of products we sell in each of the markets in which we do business;

changes in our pricing policies or in the pricing policies of our competitors or suppliers;

market acceptance of any new or enhanced versions of our products;

the availability and cost of key components and raw materials we use to manufacture our products;

## Edgar Filing: NEWPORT CORP - Form 10-Q

our ability to manufacture a sufficient quantity of our products to meet customer demand;

our ability to retain and attract key employees;

timing of new product introductions by our competitors;

fluctuations in foreign currency exchange rates; and

our levels of expenses.

We may in the future choose to change prices, increase spending, or add or eliminate products in response to actions by competitors or in an effort to pursue new market opportunities. These actions may also adversely affect our business and operating results and may cause our quarterly results to be lower than the results of previous quarters.

Page 32

---

## **Table of Contents**

In addition, we often recognize a substantial portion of our sales in the last month of the quarter. Thus, unexpected variations in timing of sales, particularly for our higher-priced, higher-margin products such as our laser products, can cause significant fluctuations in our quarterly operating results. Orders expected in one quarter could shift to another period due to changes in the anticipated timing of customers' purchase decisions or rescheduled delivery dates requested by our customers. Our operating results for a particular quarter or year may be adversely affected if our customers, particularly our largest customers, cancel or reschedule orders, or if we cannot fill orders in time due to unexpected delays in manufacturing, testing, shipping, and product acceptance. Also, we base our manufacturing on our forecasted product mix for the quarter. If the actual product mix varies significantly from our forecast, we may not be able to fill some orders during that quarter, which would result in delays in the shipment of our products and could shift sales to a subsequent period. In addition, our expenses for any given quarter are typically based on expected sales, and if sales are below expectations in any given quarter, the adverse impact of the shortfall on our operating results may be magnified by our inability to adjust spending quickly to compensate for the shortfall.

Due to these and other factors, we believe that quarter-to-quarter comparisons of results from operations, or any other similar period-to-period comparisons, should not be construed as reliable indicators of our future performance. In any period, our results may be below the expectations of market analysts and investors, which would likely cause the trading price of our common stock to drop.

### **We are dependent in part on the semiconductor equipment industry, which is volatile and unpredictable.**

A significant portion of our current and expected future business comes from sales of components, subsystems and laser products to manufacturers of semiconductor fabrication, metrology and wafer inspection equipment and sales of capital equipment to disk drive and integrated semiconductor device manufacturers. The semiconductor market has historically been characterized by sudden and severe cyclical variations in product supply and demand. The timing, severity and duration of these market cycles are difficult to predict, and we may not be able to respond effectively to these cycles. The continuing uncertainty in this market severely limits our ability to predict our business prospects or financial results in this market.

During industry downturns, our revenues from this market will decline suddenly and significantly. Our ability to rapidly and effectively reduce our cost structure in response to such downturns is limited by the fixed nature of many of our expenses in the near term and by our need to continue our investment in next-generation product technology and to support and service our products. In addition, due to the relatively long manufacturing lead times for some of the systems and, subsystems we sell to this market, we may incur expenditures or purchase raw materials or components for products we cannot sell. Accordingly, downturns in the semiconductor capital equipment market may materially harm our operating results. Conversely, when upturns in this market occur, we must be able to rapidly and effectively increase our manufacturing capacity to meet increases in customer demand that may be extremely rapid, and if we fail to do so we may lose business to our competitors and our relationships with our customers may be harmed.

### **A limited number of customers account for a significant portion of our sales to the microelectronics market, and if we lose any of these customers or they significantly curtail their purchases of our products, our results of operations would be harmed.**

Our sales to the microelectronics market (which is comprised primarily of semiconductor capital equipment and computer peripherals customers) constituted 28.8%, 33.4% and 38.0% of our consolidated net sales for the nine months ended October 1, 2005, the year ended January 1, 2005 (which included Spectra-Physics' results of operations for the period after July 16, 2004, the date of acquisition), and the year ended December 31, 2003, respectively. We rely on a limited number of customers for a significant portion of our sales to this market. Our top five customers in this market comprised approximately 51.2%, 56.5% and 62.0% of our sales to this market for the nine months ended October 1, 2005, the year ended January 1, 2005 (which included Spectra-Physics' results of operations for the period after July 16, 2004, the date of acquisition), and the year ended December 31, 2003, respectively. No single customer in this market comprised 10% or more of our consolidated net sales in the nine months ended October 1, 2005 or the year ended January 1, 2005. If any of our principal customers

## Edgar Filing: NEWPORT CORP - Form 10-Q

discontinues its relationship with us, replaces us as a vendor for certain products or suffers downturns in its business, our business and results of operations could be harmed significantly. In addition, because a relatively small number of companies dominate the front-end equipment portion of this market, and because those companies rarely change vendors in the

Page 33

## **Table of Contents**

middle of a product's life cycle, it may be particularly difficult for us to replace these customers if we lose their business.

The microelectronics market is characterized by rapid technological change, frequent product introductions, changing customer requirements and evolving industry standards. Because our customers face uncertainties with regard to the growth and requirements of these markets, their products and components may not achieve, or continue to achieve, anticipated levels of market acceptance. If our customers are unable to deliver products that gain market acceptance, it is likely that these customers will not purchase our products or will purchase smaller quantities of our products. We often invest substantial resources in developing our systems and subsystems in advance of significant sales of these systems and/or subsystems to such customers. A failure on the part of our customers' products to gain market acceptance, or a failure of the semiconductor capital equipment market to grow would have a significant negative effect on our business and results of operations.

### **Difficulties we may encounter managing a substantially larger business could adversely affect our operating results.**

Our business has recently grown significantly as a result of the acquisition of Spectra-Physics, and this growth has caused and will likely continue to cause a significant strain on our infrastructure, internal systems and managerial resources. To manage our growth effectively, we must continue to improve and expand our infrastructure, including information technology and financial operating and administrative systems and controls, and continue managing headcount, capital and operating processes in an efficient manner. Our productivity and the quality of our products may be adversely affected if we do not efficiently and effectively integrate and train our new employees and coordinate among larger and more complex management, engineering, finance, marketing, sales and customer support organizations. In addition, our information technology systems may not be capable of processing the information demands placed on them by a much larger company. Our efforts to expand our information technology systems or our inability to do so could negatively impact our business. Further, revenues may not grow at a sufficient rate to absorb the costs associated with a larger overall headcount, thus negatively impacting our profitability.

Any future growth may require significant additional resources given that, if we increase our business operations in complexity and scale, our current management capabilities and internal resources may be insufficient to manage our growth and business effectively. We cannot assure you that resources will be available when we need them or that we will have sufficient capital to fund these potential resource needs. Also, as we assess our resources following any acquisitions we may make, we will likely determine that redundancy in certain areas will require consolidation of these resources. Any organizational disruptions associated with the consolidation process could require further management attention and financial expenditures. If we are unable to manage our growth effectively, if we experience a shortfall in resources, or if we must take additional restructuring charges, our results of operations will be harmed.

### **Difficulties in executing our acquisitions could adversely impact our business.**

The Spectra-Physics acquisition, which we completed in July 2004, is the largest acquisition we have completed, and the complex process of integrating Spectra-Physics required significant resources. We continue to face ongoing business challenges that primarily include the geographic dispersion of our operations and realizing the potential benefits of the combined company's expanded product line in our end markets. Although the integration of Spectra-Physics is complete, we will continue to incur cash outflows and charges and additional costs related to this acquisition.

We have spent and will continue to spend significant resources identifying and acquiring businesses, and the efficient and effective integration of our acquired businesses into our organization is critical to our growth. The process of integrating acquired companies into our operations requires significant resources and is time consuming, expensive and disruptive to our business. Further, we may not realize the benefits we anticipate from these acquisitions because of the following significant challenges:



potentially incompatible cultural differences between the two companies;

Page 34

## Table of Contents

incorporating the acquired company's technology and products into our current and future product lines, and successfully generating marketing demand for these expanded product lines;

potential additional geographic dispersion of operations;

the diversion of our management's attention from other business concerns;

the difficulty in leveraging the acquired company's and our combined technologies and capabilities across all product lines and customer bases; and

our ability to retain key customers and employees of an acquired company.

Our failure to achieve the anticipated benefits of these and any future acquisitions or to successfully integrate the operations of the companies we acquire could also harm our business, results of operations and cash flows. Additionally, we cannot assure you that we will not incur material charges in future quarters to reflect additional costs associated with past acquisitions or any future acquisitions we may make.

**Many of the markets and industries that we serve are subject to rapid technological change, and if we do not introduce new and innovative products or improve our existing products, our business and results of operations will be negatively affected.**

Many of our markets are characterized by rapid technological advances, evolving industry standards, shifting customer needs and new product introductions and enhancements. Products in our markets often become outdated quickly and without warning. We depend to a significant extent upon our ability to enhance our existing products, to anticipate and address the demands of the marketplace for new and improved technology, either through internal development or by acquisitions, and to be price competitive. If we or our competitors introduce new or enhanced products, it may cause our customers to defer or cancel orders for our existing products. In addition, because certain of our markets experience severe cyclicality in capital spending, if we fail to introduce new products in a timely manner we may miss market upturns, and may fail to have our products or subsystems designed into our customers' products. We may not be successful in acquiring, developing, manufacturing or marketing new products on a timely or cost-effective basis. If we fail to adequately introduce new, competitive products on a timely basis, our business and results of operations would be harmed.

**We offer products for multiple industries and must face the challenges of supporting the distinct needs of each of the markets we serve.**

We offer products for a number of markets, including semiconductor capital equipment, scientific research, aerospace and defense/security, life and health sciences and fiber optic communications. Because we operate in multiple markets, we must work constantly to understand the needs, standards and technical requirements of several different industries and must devote significant resources to developing different products for these industries. Product development is costly and time consuming. We must anticipate trends in our customers' industries and develop products before our customers' products are commercialized. If we do not accurately predict our customers' needs and future activities, we may invest substantial resources in developing products that do not achieve broad market acceptance. Our decision to continue to offer products to a given market or to penetrate new markets is based in part on our judgment of the size, growth rate and other factors that contribute to the attractiveness of a particular market. If our product offerings in any particular market are not competitive or our analyses of a market are incorrect, our business and results of operations would be harmed.

**Because the sales cycle for some of our products is long and difficult to predict, and certain of our orders are subject to rescheduling or cancellation, we may experience fluctuations in our operating results.**

Many of our capital equipment, system and subsystem products are complex, and customers for these products require substantial time to make purchase decisions. These customers often perform, or require us to perform extensive configuration, testing and evaluation of our products before committing to purchasing them. The sales cycle for our capital equipment, system and subsystem products from initial contact through shipment typically

## **Table of Contents**

varies, is difficult to predict and can last as long as one year. The orders comprising our backlog are generally subject to cancellation and changes in delivery schedules by our customers without significant penalty. We have from time to time experienced order rescheduling and cancellations that have caused our revenues in a given period to be materially less than would have been expected based on our backlog at the beginning of the period. If we experience such rescheduling and/or cancellations in the future, our operating results will fluctuate from period to period. These fluctuations could harm our results of operations and cause our stock price to drop.

### **If we are delayed in introducing our new products into the marketplace, our operating results will suffer.**

Because certain of our products, particularly lasers, are sophisticated and complex, we may experience delays in introducing new products or enhancements to our existing products. If we do not introduce our new products or enhancements into the marketplace in a timely fashion, our customers may choose to use competitors' products. In addition, because certain of our markets, such as the semiconductor equipment market, are highly cyclical in nature, if we fail to timely introduce new products in advance of an upturn in the market's cycle, we may be foreclosed from selling products to many customers until the next cycle. As such, our inability to introduce new or enhanced products in a timely manner could cause our business and results of operations to suffer.

### **We face significant risks from doing business in foreign countries.**

Our business is subject to risks inherent in conducting business internationally. For the nine months ended October 1, 2005, the year ended January 1, 2005 (which included Spectra-Physics' results of operations for the period after July 16, 2004, the date of acquisition), and the year ended December 31, 2003, our international revenues accounted for approximately 46.7%, 37.8% and 31.5%, respectively, of total net sales, with a substantial portion of international sales originating in Europe and, subsequent to our acquisition of Spectra-Physics, in Japan. We expect that international revenues will continue to account for a significant percentage of total net sales for the foreseeable future, and that in particular, the proportion of our sales to Asian customers will continue to increase as a result of the purchase of Spectra-Physics. Our international operations expose us to various risks, which include:

adverse changes or instability in the political or economic conditions in countries or regions where we manufacture or sell our products;

challenges of administering our business globally;

compliance with multiple and potentially conflicting regulatory requirements including export requirements, tariffs and other trade barriers;

longer accounts receivable collection periods;

overlapping, differing or more burdensome tax structures;

adverse currency fluctuations;

differing protection of intellectual property;

difficulties in staffing and managing each of our individual foreign operations;

increased risk of exposure to terrorist activities; and

trade restrictions and licensing requirements.

In addition, fluctuations in foreign exchange rates could affect the sales price in local currencies of our products in foreign markets, potentially making our products less price competitive. Such exchange rate fluctuations could also increase the costs and expenses of our foreign operations or require us to modify our current business practices. If

## **Table of Contents**

we experience any of the risks associated with international business, our business and results of operations could be significantly harmed.

### **We face substantial competition, and if we fail to compete effectively, our operating results will suffer.**

The markets for our products are intensely competitive, and we believe that competition from both new and existing competitors will increase in the future. We compete in several specialized markets, against a limited number of companies in each market. We also face competition in some of our markets from our existing and potential customers who have developed or may develop products that are competitive to ours, or who engage subcontract manufacturers to manufacture subassembly products on their behalf. Many of our existing and potential competitors are more established, enjoy greater name recognition and possess greater financial, technological and marketing resources than we do. Other competitors are small and highly specialized firms that are able to focus on only one aspect of a market. We compete on the basis of product performance, features, quality, reliability and price and on our ability to manufacture and deliver our products on a timely basis. We may not be able to compete successfully in the future against existing or new competitors. In addition, competitive pressures may force us to reduce our prices, which could negatively affect our operating results. If we do not respond adequately to competitive challenges, our business and results of operations would be harmed.

### **If we fail to protect our intellectual property and proprietary technology, we may lose our competitive advantage.**

Our success and ability to compete depend in large part upon protecting our proprietary technology. We rely on a combination of patent, trademark and trade secret protection and nondisclosure agreements to protect our proprietary rights. The steps we have taken may not be sufficient to prevent the misappropriation of our intellectual property, particularly in foreign countries where the laws may not protect our proprietary rights as fully as in the United States. The patent and trademark law and trade secret protection may not be adequate to deter third party infringement or misappropriation of our patents, trademarks and similar proprietary rights. In addition, patents issued to us may be challenged, invalidated or circumvented. Our rights granted under those patents may not provide competitive advantages to us, and the claims under our patent applications may not be allowed. We have in the past and may in the future be subject to or may initiate interference proceedings in the United States Patent and Trademark Office, which can demand significant financial and management resources. The process of seeking patent protection can be time consuming and expensive and patents may not be issued from currently pending or future applications. Moreover, our existing patents or any new patents that may be issued may not be sufficient in scope or strength to provide meaningful protection or any commercial advantage to us. We may in the future initiate claims or litigation against third parties for infringement of our proprietary rights in order to determine the scope and validity of our proprietary rights or the proprietary rights of our competitors, which claims could result in costly litigation, the diversion of our technical and management personnel and the assertion of counterclaims by the defendants, including counterclaims asserting invalidity of our patents. For example, we have notified several manufacturers of semiconductor wafer handling robots and load ports that we believe that they are infringing upon certain of our U.S. patents, and may institute litigation against one or more of such companies in the future. We will take such actions where we believe that they are of sufficient strategic or economic importance to us to justify the cost.

### **We have experienced, and may in the future experience, intellectual property infringement claims, which could be costly and time-consuming to defend.**

We have from time to time received communications from third parties alleging that we are infringing certain trademarks, patents or other intellectual property rights held by them. Whenever such claims arise, we evaluate their merits. Any claims of infringement brought by third parties could result in protracted and costly litigation, and we could become subject to damages for infringement, or to an injunction preventing us from selling one or more of our products or using one or more of our trademarks. Such claims could also result in the necessity of obtaining a license relating to one or more of our products or current or future technologies, which may not be available on commercially reasonable terms or at all. Any intellectual property litigation and the failure to obtain necessary licenses or other rights or develop substitute technology may

## Edgar Filing: NEWPORT CORP - Form 10-Q

divert management's attention from other matters and could have a material adverse effect on our business, financial condition and results of operations. In addition, the terms of our customer contracts typically require us to indemnify the customer in the event of any claim of

Page 37

## **Table of Contents**

infringement brought by a third party based on our products. Any such claims of this kind may have a material adverse effect on our business, financial condition or results of operations.

### **If we are unable to attract new employees and retain and motivate existing employees, our business and results of operations will suffer.**

Our ability to maintain and grow our business is directly related to the service of our employees in each area of our operations. Our future performance will be directly tied to our ability to hire, train, motivate and retain qualified personnel. Competition for personnel in the technology marketplace is intense, and we have recently experienced attrition in certain management, engineering and product marketing position. If we are unable to hire sufficient numbers of employees with the experience and skills we need or to retain our employees, our business and results of operations would be harmed.

### **Our reliance on sole-source and limited source suppliers could result in delays in production and distribution of our products.**

We obtain some of the materials used to build our systems and subsystems, such as the sheet steel used in some of our vibration isolation tables, and the laser crystals used in certain of our laser products, from single or limited sources due to unique component designs as well as specialized quality and performance requirements needed to manufacture our products. If our components or raw materials are unavailable in adequate amounts at acceptable quality levels or are unavailable on satisfactory terms, we may be required to purchase them from alternative sources, if available, which could increase our costs and cause delays in the production and distribution of our products. If we do not obtain comparable replacement components from other sources in a timely manner, our business and results of operations will be harmed. Many of our suppliers require long lead-times to deliver the quantities of components that we need. If we fail to accurately forecast our needs, or if we fail to obtain sufficient quantities of components that we use to manufacture our products, then delays or reductions in production and shipment could occur, which would harm our business and results of operations.

### **Our products could contain defects, which would increase our costs and harm our business.**

Certain of our products, especially our laser and automation products, are inherently complex in design and require ongoing regular maintenance. Further, the manufacture of these products often involves a highly complex and precise process. As a result of the technical complexity of these products, design defects, changes in our or our suppliers' manufacturing processes or the inadvertent use of defective materials by us or our suppliers could adversely affect our manufacturing yields and product reliability, which could in turn harm our business, operating results, financial condition and customer relationships.

We provide warranties for our products, and we accrue allowances for estimated warranty costs at the time we recognize revenue for the sale of the products. The determination of such allowances requires us to make estimates of product return rates and expected costs to repair or replace the products under warranty. We establish warranty reserves based on historical warranty costs for our products. If actual return rates or repair and replacement costs differ significantly from our estimates, adjustments to recognize additional cost of sales may be required in future periods.

Our customers may discover defects in our products after the products have been fully deployed and operated under peak stress conditions. In addition, some of our products are combined with products from other suppliers, which may contain defects. As a result, should problems occur, it may be difficult to identify the source of the problem. If we are unable to identify and fix defects or other problems, we could experience, among other things:



loss of customers;

increased costs of product returns and warranty expenses;

damage to our brand reputation;

**Table of Contents**

failure to attract new customers or achieve market acceptance;

diversion of development and engineering resources; or

legal action by our customers.

The occurrence of any one or more of the foregoing factors could seriously harm our business, financial condition and results of operations.

**Our products are subject to potential product liability claims which, if successful, could adversely affect our results of operations.**

We are exposed to significant risks for product liability claims if personal injury or death results from the use of our products. We may experience material product liability losses in the future. We currently maintain insurance against product liability claims. However, our insurance coverage may not continue to be available on terms that we accept, if at all. This insurance coverage also may not adequately cover liabilities that we incur. Further, if our products are defective, we may be required to recall or redesign these products. A successful claim against us that exceeds our insurance coverage level, or any claim or product recall, could have a material adverse effect on our business, financial condition and results of operations.

**While we believe we currently have adequate internal control over financial reporting, we are required to evaluate our internal control over financial reporting each year, and any adverse results from such evaluation could result in a loss of investor confidence in our financial reports and have an adverse effect on our stock price.**

Pursuant to rules and regulations promulgated by the Securities and Exchange Commission under Section 404 of the Sarbanes-Oxley Act of 2002, we are required to furnish a report by our management each year on our internal control over financial reporting. This report contains, among other matters, an assessment of the effectiveness of our internal control over financial reporting as of the end of our fiscal year, including a statement as to whether or not our internal control over financial reporting is effective. This assessment must include disclosure of any material weaknesses in our internal control over financial reporting identified by management. This report must also contain a statement that our auditors have issued an attestation report on management's assessment of such internal controls.

The Committee of Sponsoring Organizations of the Treadway Commission (COSO) provides a framework for companies to assess and improve their internal control systems. Auditing Standard No. 2 provides the professional standards and related performance guidance for auditors to attest to, and report on, management's assessment of the effectiveness of internal control over financial reporting under Section 404.

Management's assessment of internal controls over financial reporting requires management to make subjective judgments and, particularly because Section 404 and Auditing Standard No. 2 are newly effective, some of the judgments will be in areas that may be open to interpretation and therefore the report may be uniquely difficult to prepare and our auditors may not agree with our assessments.

Spectra-Physics, which now constitutes over half of our business, is comprised of several separate operations with different systems and complex internal controls. In addition, because Spectra-Physics was a relatively small part of a much larger organization, their internal controls had not been subjected to extensive review in the past. As a result of these factors, our review of those internal controls over financial reporting is time-consuming and costly. While we currently believe that the internal control over financial reporting of Spectra-Physics is effective, we are still performing the system and process documentation and evaluation relating to Spectra-Physics needed to comply with Section 404 and will

## Edgar Filing: NEWPORT CORP - Form 10-Q

not complete such work until the end of 2005. During this process, if our management identifies one or more material weaknesses in our internal control over financial reporting, we will be unable to assert such internal control is effective.

If we are unable to assert each year that our internal control over financial reporting is effective (or if our auditors are unable to attest that our management's report is fairly stated or they are unable to express an opinion on the

---

**Table of Contents**

effectiveness of our internal controls), we could lose investor confidence in the accuracy and completeness of our financial reports, which would have an adverse effect on our stock price. In addition, if any such unidentified material weaknesses were to result in fraudulent activity and/or a material misstatement or omission in our financial statements, we could suffer losses and be subject to civil and criminal penalties, all of which could have a material adverse effect on our business, financial condition and results of operations.

**Our financial results will be adversely affected by changes in the accounting rules governing the recognition of stock-based compensation expense.**

We measure compensation expense for our employee stock compensation plans under the intrinsic value method of accounting prescribed by APB Opinion No. 25, Accounting for Stock Issued to Employees. Recently, the Financial Accounting Standards Board has adopted changes to the accounting rules concerning the recognition of stock option compensation expense which would require us to account for equity compensation under the fair value method of accounting prescribed by SFAS No. 123R, Share-Based Payment. We provide disclosures of our operating results as if we had applied the fair value method of accounting on a pro forma basis in accordance with SFAS No. 123, Accounting for Stock-Based Compensation. In accordance with Release 33-8568, issued by the Securities and Exchange Commission in April 2005, beginning in the first quarter of 2006, we and other companies currently using the intrinsic value method will be required to measure compensation expense using the fair value method, which will adversely affect our results of operations by significantly increasing our equity compensation expense.

**Compliance with environmental regulations and potential environmental liabilities could adversely affect our financial results.**

Our operations are subject to various federal, state and local environmental protection regulations relating to the protection of the environment, including those governing discharges of pollutants into the air and water, the management and disposal of hazardous substances and wastes and the cleanup of contaminated sites. In the United States, we are subject to the federal regulation and control of the Environmental Protection Agency. Comparable authorities are involved in other countries. Some of our operations require environmental permits and controls to prevent and reduce air and water pollution, and these permits are subject to modification, renewal and revocation by issuing authorities. Future developments, administrative actions or liabilities relating to environmental matters could have a material adverse effect on our business, results of operations or financial condition.

Although we believe that our safety procedures for using, handling, storing and disposing of such materials comply with the standards required by state and federal laws and regulations, we cannot completely eliminate the risk of accidental contamination or injury from these materials. In the event of such an accident involving such materials, we could be liable for damages and such liability could exceed the amount of our liability insurance coverage (if any) and the resources of our business.

Spectra-Physics Mountain View, California facility is an EPA-designated Superfund site and is subject to a cleanup and abatement order from the California Regional Water Quality Control Board. Spectra-Physics, along with several other entities with facilities located near the Mountain View, California facility, have been identified as Responsible Parties with respect to this Superfund site, due to releases of hazardous substances during the 1960s and 1970s. The site is mature, and investigations and remediation efforts have been ongoing for approximately 20 years. Spectra-Physics and the other Responsible Parties have entered into a cost-sharing agreement covering the costs of remediating the off-site groundwater impact. We have established reserves relating to the estimated cost of these remediation efforts, however our ultimate costs of remediation are difficult to predict. In addition, while we are not aware of any unresolved property damage or personal injury claims relating to this site, such claims could be made against us in the future. While Thermo Electron Corporation has agreed in connection with our purchase of Spectra-Physics to indemnify us, subject to certain conditions, for environmental liabilities relating to this site in excess of our reserves, this indemnity may not cover all liabilities relating to this site. In such event, our business, financial condition and results of operations could be adversely affected.



## **Table of Contents**

### **Natural disasters or power outages could disrupt or shut down our operations, which would negatively impact our operations.**

We are headquartered, and have significant operations, in the State of California and other areas where our operations are susceptible to damages from earthquakes, floods, fire, loss of power or water supplies, or other similar contingencies. If any of our facilities were to experience a catastrophic loss or significant power outages, it could disrupt our operations, delay production, shipments and revenue, and result in large expenses to repair or replace the facility, any of which would harm our business. We are predominantly uninsured for losses and interruptions caused by earthquakes.

### **ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

The principal market risks (i.e., the risk of loss arising from adverse changes in market rates and prices) to which we are exposed are foreign exchange rates which may generate translation and transaction gains and losses and interest rate risk.

#### **Foreign Currency Risk**

Operating in international markets sometimes involves exposure to volatile movements in currency exchange rates. The economic impact of currency exchange rate movements on our operating results is complex because such changes are often linked to variability in real growth, inflation, interest rates, governmental actions and other factors. These changes, if material, may cause us to adjust our financing and operating strategies. Consequently, isolating the effect of changes in currency does not incorporate these other important economic factors.

From time to time we use forward exchange contracts to mitigate the risks associated with certain foreign currency transactions entered into in the ordinary course of business, primarily foreign currency denominated receivables and payables. We do not engage in currency speculation. The forward exchange contracts generally require us to exchange U.S. dollars for foreign currencies at maturity, at rates agreed to at inception of the contracts. If the counterparties to the exchange contracts (AA or A+ rated banks) do not fulfill their obligations to deliver the contracted currencies, we could be at risk for any currency related fluctuations. Transaction gains and losses are included in our current net income (loss) in our statement of operations. Net foreign exchange gains and losses were not material to our reported results of operations for the last three years.

Our operating income from international operations totaled \$5.3 million for the nine months ended October 1, 2005. As currency exchange rates change, translation of the income statements of international operations into U.S. dollars affects the year-over-year comparability of our operating results. We do not generally hedge translation risks because cash flows from international operations are generally reinvested locally. We do not enter into hedges to minimize volatility of reported earnings because we do not believe it is justified by the exposure or the cost.

Changes in currency exchange rates that would have the largest impact on translating future international operating profit include the euro, Japanese yen, British pound, Canadian dollar and Taiwan dollar. We estimate that a 10% change in foreign exchange rates would not have had a material effect on reported net loss for the quarter ended October 1, 2005. We believe that this quantitative measure has inherent limitations because, as discussed in the first paragraph of this section, it does not take into account any governmental actions or changes in either customer purchasing patterns or financing and operating strategies.

#### **Interest Rate Risk**

The interest rates we pay on certain of our debt instruments are subject to interest rate risk. Our collateralized line of credit bears interest at either the prevailing prime rate, or the prevailing London Interbank Offered Rate plus 1.5%, at our option. Our investments in marketable securities, which totaled \$30.9 million at October 1, 2005, are sensitive to changes in the general level of U.S. interest rates. We estimate that a 10% change in the interest rate earned on our investment portfolio or a 10% change in interest rates on our lines of credit would not have had a material effect on our net income (loss) for either the three or nine months ended October 1, 2005.

**Table of Contents**

The sensitivity analyses described in the interest rate and foreign exchange discussions above disregard the possibility that rates can move in opposite directions and that gains from one category may or may not be offset by losses from another category and vice versa.

**ITEM 4. CONTROLS AND PROCEDURES**

**(a) Evaluation of Disclosure Controls and Procedures**

Our chief executive officer and our chief financial officer, after evaluating our disclosure controls and procedures (as defined in Securities Exchange Act of 1934 (the Exchange Act) Rules 13a-15(e) and 15-d-15(e)) as of the end of the period covered by this Quarterly Report on Form 10-Q (the Evaluation Date), have concluded that as of the Evaluation Date, our disclosure controls and procedures are effective to ensure that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms, and to ensure that information required to be disclosed by us in such reports is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure.

**(b) Changes in Internal Control Over Financial Reporting**

There was no change in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. We continue to enhance our internal control over financial reporting, primarily by evaluating and enhancing our process and control documentation and increasing our systems security, in connection with our ongoing efforts to meet the requirements of Section 404 of the Sarbanes-Oxley Act of 2002. We discuss with and disclose these matters to the Audit Committee of our Board of Directors and our auditors.



**Table of Contents****PART II OTHER INFORMATION****ITEM 5. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

The following table reflects purchases made by us during the quarter ended October 1, 2005, of equity securities that are registered by us pursuant to Section 12 of the Securities Exchange Act of 1934, as amended:

<u>Period<sup>(1)</sup></u>	<u>Total Number of Shares (or Units) Purchased</u>	<u>Average Price Paid per Share (or Unit)</u>	<u>Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs</u>	<u>Maximum Number (or Approximate Dollar Value of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs</u>
July 3, 2005 July 30, 2005				
July 31, 2005 August 27, 2005 <sup>2)</sup>	9,293	\$ 13.71		
August 28, 2005 October 1, 2005				
<b>Totals</b>	<b>9,293</b>	<b>\$ 13.71</b>		

(1) The periods reported conform to our fiscal calendar which consists of two periods of four weeks and one period of five weeks in each fiscal quarter.

(2) In August 2005, we received and cancelled 9,293 shares of common stock in payment of taxes owed on ordinary income recognized by certain employees upon the vesting of shares of restricted stock issued to them under our 2001 Stock Incentive Plan. At the time they were received, these shares had a value of \$13.71 per share for a total of \$0.1 million.

**ITEM 6. EXHIBITS**

<u>Exhibit Number</u>	<u>Description of Exhibit</u>
31.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 (the Exchange Act).
31.2	Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act.
32.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Exchange Act and 18 U.S.C. Section 1350.
32.2	Certification of Chief Financial Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Exchange Act and 18 U.S.C. Section 1350.



**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: November 10, 2005

NEWPORT CORPORATION

By: */s/ Charles F. Cargile*  
Charles F. Cargile,  
Senior Vice President, Chief Financial Officer and Treasurer  
(Principal Financial Officer and Duly Authorized Officer)

Page 44

**Table of Contents**

**EXHIBIT INDEX**

<b><u>Exhibit Number</u></b>	<b><u>Description of Exhibit</u></b>
31.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 (the Exchange Act ).
31.2	Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act.
32.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Exchange Act and 18 U.S.C. Section 1350.
32.2	Certification of Chief Financial Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Exchange Act and 18 U.S.C. Section 1350.